Method for predicting efficacy of bispecific fusion polypeptide in subject
By employing biomarkers to predict the efficacy of bispecific fusion polypeptides targeting IL-6R and IL-17a, the method addresses the challenge of costly treatments for SSc, enabling personalized and effective therapy for systemic sclerosis.
Patent Information
- Application Number
- PCT/JP2024/016781
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-02
- Filing Date
- 2024-05-01
- Publication Date
- 2024-11-07
AI Technical Summary
Current treatments for systemic sclerosis (SSc) lack a definitive cure, and existing drugs are costly, necessitating a method to predict the efficacy of bispecific fusion polypeptides targeting IL-6R and IL-17a for personalized treatment.
The use of biomarkers such as IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1 to predict the efficacy of bispecific fusion polypeptides by determining their levels in patient samples, allowing for targeted administration of a pharmaceutical composition comprising a finomer sequence that binds to IL-17a and forms a complex with an IL-6R antibody.
This approach enables effective prediction and administration of bispecific fusion polypeptides, potentially improving SSc symptoms by identifying subjects likely to benefit from the treatment, thereby optimizing drug use and patient outcomes.
Smart Images

Figure JPOXMLDOC01-APPB-I000001 
Figure JPOXMLDOC01-APPB-I000002 
Figure JPOXMLDOC01-APPB-I000003
Abstract
Description
Methods for predicting efficacy of a bispecific fusion polypeptide in a subject
[0001] This patent application claims priority to Japanese Patent Application No. 2023-076072, the entire contents of which are incorporated herein by reference. The present disclosure relates to methods for predicting the efficacy of a bispecific fusion polypeptide in a subject.
[0002] Systemic sclerosis (SSc) is a chronic disease characterized by hardening of the skin and internal organs. The etiology of SSc is complex, and its pathology has not been fully elucidated, but associations with immune abnormalities, fibrosis, and vascular disorders have been suggested. Currently, there are no drugs that can completely cure SSc, and drugs that are known to have some effect on the symptoms of SSc include steroids, cyclophosphamide, proton pump inhibitors, prostacyclin, ACE inhibitors, and endothelin receptor antagonists.
[0003] Recently, the anti-interleukin-6 receptor (IL-6R) antibody tocilizumab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of interstitial lung disease associated with SSc. Furthermore, clinical trials in Japan have shown that the anti-interleukin-17 receptor (IL-17R) A antibody brodalumab is effective in treating skin symptoms associated with SSc, and an application for approval has been submitted. Meanwhile, a fusion polypeptide with bispecificity for IL-6R and interleukin-17a (IL-17a) is known as a drug that can be used to treat autoimmune diseases (Patent Document 1), and it is expected to be effective in treating SSc. However, because antibody drugs are generally expensive, it is desirable to identify patients who are likely to respond to the fusion polypeptide and administer it appropriately.
[0004] International Publication No. 2015 / 141862
[0005] One object of the present disclosure is to provide a method for predicting the efficacy of a bispecific fusion polypeptide in a subject.
[0006] The inventors have found that IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR and SPON1 can be used as biomarkers to predict the efficacy of bispecific fusion polypeptides.
[0007] Thus, in one aspect, there is provided a method for predicting the efficacy of a bispecific fusion polypeptide in a subject, the method comprising comparing the level of a biomarker molecule in a sample taken from the subject to a cutoff value for said biomarker molecule, wherein the subject has systemic sclerosis, the biomarker molecule is at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1, and the bispecific fusion polypeptide comprises a phenomeric sequence that binds to IL-17a and IL-6R in complex with an antibody that binds to IL-6R or a subsequence thereof that has IL-6R binding ability.
[0008] In one aspect, a pharmaceutical composition for treating systemic sclerosis or a symptom thereof is provided, which is administered to a subject predicted by the above-described method to be effective against a bispecific fusion polypeptide, and which comprises a bispecific fusion polypeptide that binds to IL-17a and includes a phenomeric sequence complexed with an antibody that binds to IL-6R or a subsequence thereof that has IL-6R binding ability.
[0009] In one aspect, a kit for predicting the efficacy of a bispecific fusion polypeptide in a subject is provided, comprising at least one reagent that specifically binds to at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1, wherein the subject has systemic sclerosis, and the bispecific fusion polypeptide comprises a phenomeric sequence that binds to IL-17a and IL-6R in complex with an antibody that binds to IL-6R or a subsequence thereof that has IL-6R binding ability.
[0010] Following the disclosure of the present application, the efficacy of a bispecific fusion polypeptide in a subject can be predicted.
[0011] Figure 1 shows an overview of the process used to identify biomarker molecules. a. The relative values of IL-6 and IL-17A are shown in the SSc classification according to the ACR classification criteria (2013). The Y-axis shows NPX values (Olink log2 scale relative protein quantification units). Samples exceeding the 95th percentile of healthy samples were defined as positive samples. Positive samples are shown in dark gray. *Adjusted P value < 0.05 (FDR); significant difference between the SSc and HC groups (linear model using Limma). b. The proportion of patients with high blood levels of IL-6 and / or IL-17A is shown. The clinical characteristics of patients classified by blood levels of IL-6 and IL-17A are shown. †P value < 0.05; significant difference between each cluster and the "Negative" cluster (Welch's two-sample t-test). ‡P value < 0.05: significant difference between each cluster and the "Negative" cluster (Fisher's exact test). Figure 1 shows proteins differentially expressed in patients with high blood levels of IL-6 and IL-17A. a. Volcano plot of the difference in protein abundance between the HC group and each cluster, with fold change on the X-axis and p-value (significant difference) on the Y-axis. Significantly up-regulated proteins are shown in dark gray, and significantly down-regulated proteins are shown in light gray. b. Venn diagram showing the overlap of differentially expressed proteins. This is a heat map created using 32 differentially expressed proteins (DEPs) correlated with %DLCO. The expression level of each protein (row) was normalized to a mean expression level of 0 and a standard deviation of 1. Patients with relatively high expression of a particular protein are shown in dark colors, while patients with relatively low expression are shown in light colors. Proteins (rows) and patients (columns) were rearranged by hierarchical clustering (distance: Euclidean, method: Ward). Patient information is annotated along the columns.
[0012] Thirty-two differentially expressed proteins (DEPs) associated with %DLCO divided SSc patients into groups with moderate-to-severe and moderate lung dysfunction. The %DLCO of these clusters is shown. This heatmap was created using 34 differentially expressed proteins (DEPs) correlated with PAH. The expression level of each protein (rows) was normalized to a mean expression level of 0 and a standard deviation of 1. Patients with relatively high expression of a particular protein are shown in darker shades, while patients with relatively low expression are shown in lighter shades. Proteins (rows) and patients (columns) were re-arranged using hierarchical clustering (distance: Euclidean, method: Ward). Patient information is annotated in the columns. a. Thirty-four DEPs associated with PAH divided SSc patients into three major clusters. The prevalence of PAH in these clusters is shown. b. The %FVC / %DLCO ratio in these clusters is shown. The dashed line indicates a ratio of 1.6 (cutoff value). #p-value<0.05; significant difference between each cluster (Welch's two-sample t-test). The color of each point represents the patient cluster. Serum protein levels (left panel) and gene expression (right panel) of IL-6 are shown. #p-value<0.05; significant difference between each cluster and HC (Welch's two-sample t-test). *p-value<0.05; significant difference between stimulation (Stim) and no stimulation (No_stim) (Welch's two-sample t-test). $p-value<0.05; significant difference between antibody treatment and stimulation (Welch's two-sample t-test). Serum protein levels (left panel) and gene expression (right panel) of GDF-15 are shown. #p-value<0.05; significant difference between each cluster and HC (Welch's two-sample t-test). *p-value<0.05; significant difference between stimulation and no stimulation (Welch's two-sample t-test). $p value < 0.05; significant difference between antibody treatment and stimulation (Welch's two-sample t-test).
[0013] LTBP-2 serum protein levels (left panel) and gene expression (right panel) are shown. #p value < 0.05; significant difference between each cluster and HC (Welch's two-sample t-test). *p value < 0.05; significant difference between stimulation and no stimulation (Welch's two-sample t-test). $p value < 0.05; significant difference between antibody treatment and stimulation (Welch's two-sample t-test). CCL7 serum protein levels (left panel) and gene expression (right panel) are shown. #p value < 0.05; significant difference between each cluster and HC (Welch's two-sample t-test). *p value < 0.05; significant difference between stimulation and no stimulation (Welch's two-sample t-test). $p value < 0.05; significant difference between antibody treatment and stimulation (Welch's two-sample t-test). CHI3L1 serum protein levels (left panel) and gene expression (right panel) are shown. #p-value<0.05; significant difference between each cluster and HC (Welch's two-sample t-test). *p-value<0.05; significant difference between stimulation and no stimulation (Welch's two-sample t-test). $p-value<0.05; significant difference between antibody treatment and stimulation (Welch's two-sample t-test). Serum protein levels (left panel) and gene expression (right panel) of EFEMP1 are shown. #p-value<0.05; significant difference between each cluster and HC (Welch's two-sample t-test). *p-value<0.05; significant difference between stimulation and no stimulation (Welch's two-sample t-test). $p-value<0.05; significant difference between antibody treatment and stimulation (Welch's two-sample t-test). Serum protein levels (left panel) and gene expression (right panel) of PLAUR are shown. #p-value<0.05; significant difference between each cluster and HC (Welch's two-sample t-test). *p-value<0.05; significant difference between stimulation and no stimulation (Welch's two-sample t-test). $p-value<0.05; significant difference between antibody treatment and stimulation (Welch's two-sample t-test).
[0014] The serum protein level (left panel) and gene expression (right panel) of SPON1 are shown. #p-value < 0.05; significant difference between each cluster and HC (Welch's two-sample t-test). $p-value < 0.05; significant difference between antibody treatment and stimulation (Welch's two-sample t-test). The classification performance of PAH clusters 1 and 3 using GDF15, LTBP2, CHI3L1, EFEMP1, PLAUR, and SPON1 is shown. a. Principal component analysis results using six molecules. b. Factor loadings in principal component analysis. c. Receiver operating characteristic (ROC) analysis results for each molecule. The classification performance of each molecule for PAH cluster 1 (left panel) and PAH cluster 3 (right panel) is shown. d. The results of a comparison of the classification performance of a classification model constructed using six molecules with random forest (RF), a machine learning algorithm, and the classification performance of each molecule. The results are shown as Area Under the Curve (AUC) of ROC analysis. The classification performance for PAH cluster 1 (left) and PAH cluster 3 (right) are shown. e. The importance of six molecules in a classification model constructed using random forest (RF) is shown. DLCO cluster classification performance using IL-6, GDF15, LTBP2, CCL7, EFEMP1, and SPON1 is shown. a. Principal component analysis results using six molecules. b. Factor loadings in principal component analysis. c. Receiver operating characteristic (ROC) analysis results for each molecule. The classification performance of the DLCO cluster for each molecule is shown. d. The results of a comparison of the classification performance of a classification model constructed using six molecules with random forest (RF), a machine learning algorithm, and the classification performance of each molecule are shown. The results are shown as Area Under the Curve (AUC) of ROC analysis. Fig. 1 shows the classification performance of the DLCO cluster. e) Shows the importance of six molecules in a classification model constructed with random forest (RF).
[0015] Bispecific Fusion Polypeptides In the present disclosure, a bispecific fusion polypeptide comprises a fynomer sequence that binds to interleukin-17a (IL-17a) and forms a complex with an antibody or subsequence thereof that binds to interleukin-6 receptor (IL-6R), also referred to as a FynomAb. The bispecific fusion polypeptide may be a fusion polypeptide that simultaneously binds to IL-17a and IL-6R.
[0016] In one embodiment, the finomer sequence may be complexed with the heavy or light chain sequence, or a subsequence of the heavy or light chain sequence, of an antibody that binds to IL-6R. The finomer sequence may be complexed with the amino or carboxyl terminus of the antibody heavy chain sequence or a subsequence thereof. The finomer sequence may be complexed with the amino or carboxyl terminus of the antibody light chain sequence or a subsequence thereof.
[0017] A bispecific fusion polypeptide may comprise one or more IL-17a-binding sequences complexed with an IL-6R-binding antibody or subsequence thereof. In certain embodiments, a bispecific fusion polypeptide may comprise two or more, e.g., 3, 4, 5, 6, 7, or 8, IL-17a-binding phenomeric sequences complexed with an IL-6R-binding antibody or subsequence thereof.
[0018] The IL-17a binding phenomer sequence may be of various lengths. In one embodiment, the phenomer sequence is about 10 to 80 amino acids in length.
[0019] The IL-17a binding phenomeric sequences can be sequences with varying affinities for IL-17a. -9 About 10 minutes from M -13 The binding affinity of M (K d In a preferred embodiment, the phenomeric sequence may have a binding affinity (K) for glycosylated IL-17a of about 1 to about 200 nM. d In a further preferred embodiment, the phenomeric sequence may have a binding affinity (K) for glycosylated human IL-17a of about 1 to about 200 nM, or about 5 to about 50 nM. d The phenomeric sequence may have the binding affinity (K) of the phenomeric sequence of SEQ ID NO: 1 for glycosylated IL-17a. d or KD) for glycosylated IL-17a.
[0020] The IL-17a binding phenomer sequence can be a sequence that has identity to a reference phenomer sequence. In certain embodiments, the Finomer sequence can be a sequence having at least 90% or more (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to any of the following reference sequences: GVTLFVALYDYKQKGHLDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (aka 11L0-C6) (SEQ ID NO: 2); GVTLFVALYDYSARGQLDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (aka 11L5-B06) (SEQ ID NO: 3); GVTLFVALYDYESVSWSDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (aka 11L9-C09) (SEQ ID NO: 5); GVTLFVALYDYSSRGVLDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (aka 11L10-A05) (SEQ ID NO: 6); GVTLFVALYDYANHGNRDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (aka 1L3-B9) (SEQ ID NO: 1); GVTLFVALYDYDKLSALDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (aka 11L6-F03) (SEQ ID NO: 4); and GVTLFVALYDYSRKSNLDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (aka 11L11-A09) (SEQ ID NO: 7).
[0021] The IL-17a-binding Fynomer sequence may be a sequence having amino acid substitutions, insertions, additions, or deletions relative to the above reference Fynomer sequence. In one embodiment, the Fynomer sequence may be any of the amino acid sequences set forth in SEQ ID NOs: 1-7, or any of the amino acid sequences set forth in SEQ ID NOs: 1-7 with 1-2, 2-3, 3-4, 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-25, or 25-30 conservative, non-conservative, or conservative and non-conservative amino acid substitutions, or any of the amino acid sequences set forth in SEQ ID NOs: 1-7 with 1-2, 2-3, 3-4, 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-25, or 25-30 amino acid deletions or insertions.
[0022] In one embodiment, an IL-17a-binding phenomer sequence may contain a specific motif sequence identical to a sequence contained in a reference phenomer sequence. In one embodiment, one or more of the motifs GVTLFVALYDY (SEQ ID NO:30), DLSFHKGEKFQIL (SEQ ID NO:31), STHEYE (SEQ ID NO:32), STHEYED (SEQ ID NO:33), WWEAR (SEQ ID NO:34), DWWEAR (SEQ ID NO:35), and SLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO:36) are included in an IL-17a-binding phenomer sequence used in the present disclosure. In a specific embodiment, the phenomer sequence may contain the sequence STHEYE at amino acid positions 31-36 of the sequence, or the sequence QILSTHEYEDWWEAR (SEQ ID NO:37) at amino acid positions 28-42 of the sequence.
[0023] The IL-17a-binding finomer sequence can be a sequence having specific amino acid residues at specific positions or locations. In particular, the finomer sequence can have an E residue located immediately after the src loop sequence and / or an E residue located immediately after the src loop sequence, STHEY (SEQ ID NO:38).
[0024] The IL-17a-binding fibromer sequence can be a sequence having a specific activity or function. In one embodiment, the fibromer sequence can bind to IL-17a and inhibit, reduce, or suppress IL-17 receptor function or signaling. In a further embodiment, the fibromer sequence can bind to glycosylated IL-17a and inhibit, reduce, or suppress IL-17 receptor function or signaling. In yet another embodiment, the fibromer sequence can bind to glycosylated IL-17a and inhibit, reduce, or suppress IL-6 production by fibroblasts. For example, the fibromer sequence can inhibit, reduce, or suppress IL-6 production by fibroblasts with an IC of about 10 to about 250 nM or about 10 to about 100 nM. 50 may have:
[0025] The bispecific fusion polypeptide comprises an antibody or subsequence of the antibody that binds to IL-6R, e.g., a VH or VL chain that binds to IL-6R. In one embodiment, the antibody or subsequence has a specific binding affinity of about 10 for binding to IL-6R. -5 About 10 minutes from M -13 The binding affinity of M (K d ) may be included.
[0026] The IL-6R-binding antibody or a subsequence thereof, such as a VH or VL chain, may be a sequence having various lengths. In particular, the sequence may be a sequence having a length of about 50 to 100 amino acids. In a particular embodiment, the antibody or a subsequence thereof may be a Fab, Fab', F(ab') 2 , Fv, Fd, single-chain Fv (scFv), disulfide-linked Fv (sdFv), V L , V H , diabody ((V L -V H ) 2 Or (V H -V L ) 2 ), triabody (trivalent antibody), tetrabody (tetravalent antibody), minibody ((scF V -C H 3) 2 ), IgGdeltaCH2, scFv-Fc or (scFv) 2 - It may be an Fc fragment.
[0027] The IL-6R binding antibody or subsequence thereof may be a sequence having various isotypes. In some embodiments, the antibody may be of the IgG, IgA, IgE, IgM, or IgD isotype.
[0028] The IL-6R binding antibody or subsequence thereof may be a sequence having significant identity to the reference sequences set forth below. In certain embodiments, the antibody or subsequence thereof may be a sequence having at least 90% or more (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to any of the following heavy chain (HC) and light chain (LC) sequences: (HC)QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQ GSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 12); (LC)DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).
[0029] The IL-6R-binding antibody or subsequence thereof may have one or more amino acid substitutions, insertions, additions, or deletions relative to a single reference sequence. In a specific embodiment, the antibody or subsequence thereof may have the heavy chain (HC) sequence of SEQ ID NO: 12 and the light chain (LC) sequence of SEQ ID NO: 13, or a sequence having 1-2, 2-3, 3-4, 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-25, or 25-30 conservative, non-conservative, or conservative and non-conservative amino acid substitutions, or amino acid insertions or deletions within or outside the variable chain sequence of either the heavy chain (HC) or light chain (LC) sequences described above.
[0030] The IL-6R binding antibody or subsequence thereof can have any of the heavy chain (HC) and / or light chain (LC) sequences set forth below: (HC) QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVT AADTAVYYCARSLARTTAMDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGGGSGGGGSGGGGGSGVTLFVALYDYKQKGHLDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 14); (LC) DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 15) (aka COVA 801);(GC)QVQLQESGPGVVRPSQTLSLTCTVSGISITSD1AWIGVRQAGAGEEIGIIIGTTOKIK5REAAD - TCPPCPAPELLGGSVFLFP5KPKDTLMISRPEEVTCVVDVHEDPEVKETEEEQENIERVVVETEHDTD KGQPREPQVYTLPPSREEMTOQVLTCLVKGKOSDIAVETENGGGEEIKTTDUVDDGGIEIIKTTVDKIREQGEEEEEOEEILLIEE (LC)DIQMTQ@SSLSASVGDRVTITCRASQDISOLNEEQKKGKAPKLIIITSALHS TISSLQPEDIATYCQGGNTLPYTFGGGTKVEIKRTOAAPSVEID@SDEQLKSGTASENNDOO DNA GGGVTLFVALYDYKQKGHLDLSKHKGEKKQILSTHHEYEDWWEARSLTTGGIOIPSNYVAPVDSIQGGクVA 802);(HC)QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQ@GRGLEWIGIIISGITTINPS The PSSKSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSLTSLTVPSLT The The The VALYDYSARGQLDLSFHKGEKQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ; (LC)DIQMTESPSLSATETETCRASTE(GC)QVQLQESGPGVVRPSQTLSLTCTVSGISITSD1AWIGVRQAGAGEEIGIIIGTTOKIK5REAAD - TCPPCPAPELLGGSVFLFP5KPKDTLMISRPEEVTCVVDVHEDPEVKETEEEQENIERVVVETEHDTD KGQPREPQVYTLPPREEMTKNVVLTCLVKGEYSDIAVETENGGEENEKTTDUVLDDGIDOY5ITTODKIREQGEEEEEEEEEEIEEE (LC)DIQMTQ@SSLSASVGDRVTITCRASQDISOLNEEQKKGKAPKLIIITSALHS TISSLQPEDIATYCQGGNTLPYTFGGGTKVEIKRTOAAPSVEID@SDEQLKSGTASENNDOO DNA GSGVTLFVALYDYSARGQLDLSKHKGEKKQILSTHHEYEDWWEARSLTTRGGNIPSNYVAPVDSIQGGクVA 804);(HC)QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQ@GRGLEWIGIIISGITTINPS The PSSKSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSLTSLTVPSLT The The The VALYDYESVSWSDLSFHKGEKQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ; (LC)DIQMTESPSLSATETETCRASTE(GC)QVQLQESGPGVVRPSQTLSLTCTVSGISITSD1AWIGVRQAGAGEEIGIIIGTTOKIK5REAAD - TCPPCPAPELLGGSVFLFP5KPKDTLMISRPEEVTCVVDVHEDPEVKETEEEQENIERVVVETEHDTD KGQPREPQVYTLPPSREEMTOQVLTCLVKGEISDIAVETENGGEENEKTTDDVLDDGIDOYKETTODKSREQGEEEEEEQEILLIGE (LC)DIQMTQ@SSLSASVGDRVTITCRASQDISOLNEEQKKGKAPKLIIITSALHS TISSLQPEDIATYCQGGNTLPYTFGGGTKVEIKRTOAAPSVEID@SDEQLKSGTASENNDOO DNA GGGVTLFVALYDYESVSWSDLSKHKGEKQILSTHHEYEDWWEARSLTTNIGNIPSNYVAPVDSIQGGクVA 806);(HC)QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQ@GRGLEWIGIIISGITTINPS The PSSKSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSLTSLTVPSLT The The The VALYDYSSRGVLDLSFHKGEKQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ; (LC)DIQMTESPSLSATETETCRASTE(HC)QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQ GSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 28); (LC)DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTF TISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGGSGVTLFVALYDYSSRGVLDLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 29) (aka COVA 808), or sequences having 1-2, 2-3, 3-4, 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-25, 25-30 conservative, non-conservative, or conservative and non-conservative amino acid substitutions, or amino acid insertions or deletions, within or outside the variable chain sequence of any of the heavy chain (HC) or light chain (LC) sequences listed above;
[0031] The IL-6R-binding antibody may be a known IL-6R antibody such as tocilizumab. The antibody subsequence may be a sequence having an amino acid substitution, insertion, or deletion within or outside the heavy or light chain of the antibody, or the variable region sequence of the heavy or light chain. The subsequence may be a sequence having an amino acid substitution, insertion, or deletion within or outside the complementarity-determining region (CDR) of the antibody heavy or light chain variable region sequence. The subsequence may be a sequence having an amino acid substitution, insertion, or deletion within or outside the framework region (FR) of the heavy or light chain variable region sequence of a known IL-6R-binding antibody.
[0032] The IL-6R binding sequence may be a sequence having a specific activity or function. In one embodiment, the IL-6R binding sequence binds to IL-6R and inhibits, reduces, or suppresses the function or signal transduction of IL-6R.
[0033] In the present disclosure, an IL-6R-binding antibody, a subsequence thereof, or a VH or VL chain and a phenomeric sequence thereof can be linked directly or via a linker. In one embodiment, the linkage can be a covalent bond or an amide bond. In another embodiment, the linkage can be via a linker. Non-limiting examples of linkers can include peptides and carbon chain sequences. In one embodiment, peptide sequences having about 1-5, 5-10, 10-15, 15-20, 20-25, 25-50, or 50-100 amino acid residues; and carbon chains having about 1-5, 5-10, 10-15, 15-20, 20-25, 25-50, or 50-100 carbon atoms can be used as linkers. An example of a linker peptide is (GGGGS). X (X=1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) (SEQ ID NO: 39) or GGGGSGGGGGSGGGGS (SEQ ID NO: 40).
[0034] The target sequences to which the bispecific fusion polypeptide binds include mammalian IL-17a and IL-6R. In a particular embodiment, the target is human IL-17a and / or IL-6R.
[0035] The term "Fynomer" refers to a non-immunoglobulin-derived binding (poly)peptide based on or derived from the human Fyn kinase SH3 domain, modeled after the so-called scaffold described in Gebauer and Skerra (2009) Curr Opinion in Chemical Biology 13:245-255. The SH3 domain of human Fyn kinase can be used as a scaffold to engineer proteins (termed fynomers) that bind with high affinity and specificity to different targets, such as proteins (WO2008 / 022759, WO2011 / 023685, Grabulovski D. et al. (2007) J Biol Chem 282, pp. 3196-3204, Bertschinger J. et al. (2007) Protein Eng Des Sel, 20, pp. 57-68, and Schlatter et al. (2012) mAbs, 4(4) pp. 497-50). The sequence of the Fyn3 sequence is shown below, with the RT loop (EARTED) (SEQ ID NO: 41) and src loop (NSSE) (SEQ ID NO: 42) regions underlined, respectively: (SEQ ID NO: 43)
[0036] "IL-17a finomer" or "anti-IL-17a finomer" and grammatical variations thereof refer to a finomer sequence that binds to interleukin-17a (IL-17a) protein. The amino acid positions within the RT loop and src loop are believed to determine the binding specificity for glycosylated IL-17A. Representative IL-17a-binding finomer sequences (SEQ ID NOs: 1-7) are shown below:
[0037] "IL-6R antibody" or "anti-IL-6R antibody" and grammatical variations thereof refer to a polyclonal or monoclonal antibody that binds to the interleukin-6 receptor (IL-6R) protein. Representative IL-6R-binding antibody heavy and light chain sequences (SEQ ID NOs: 8 and 9) are shown below: Tocilizumab heavy chain sequence (SEQ ID NO: 8), CDRs are underlined. Tocilizumab light chain sequence (SEQ ID NO: 9), CDRs are underlined.
[0038] Further examples of IL-6R binding antibodies and / or heavy and light chain sequences of antibodies that bind to IL-6R are described in US20130122012; US20120225060; US20120128626; and US20120077731. Nanobodies that bind to IL-6R are described in WO2008 / 020079.
[0039] As used herein, the terms "IL-17a," "IL-17a protein," "IL-17a sequence," and "IL-17a domain" refer to all or a portion (e.g., a subsequence such as an antigenic region or epitope) of an IL-17a protein sequence isolated from, based on, or present in any naturally occurring state, or artificially created (e.g., genetically engineered) IL-17a. Thus, the term IL-17a, etc., includes cellular as well as recombinantly or synthetically produced IL-17a sequences.
[0040] As used herein, the terms "IL-6R, IL-6R protein," IL-6R sequence, and IL-6R domain" refer to all or a portion of an IL-6R protein sequence (e.g., a subsequence such as an antigenic region or epitope) isolated from, based on, or present in any naturally occurring state, or an artificially created (e.g., genetically engineered) IL-6R. Thus, the terms IL-6R and the like include cellular as well as recombinantly or synthetically produced IL-6R sequences.
[0041] Mammalian IL-17a and IL-6R sequences are known to those of skill in the art. A representative, non-limiting example of a human IL-17a protein sequence (SEQ ID NO: 10) is: MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVA
[0042] A representative, non-limiting example of a human IL-6R protein sequence (SEQ ID NO: 11) is: MLAVGCALLAALLLAAPGAALAPRRCPAQEVARGVLTSLPGDSVTLTCPGVEPEDNATVHWVLRKPAAGSHPSRWAGMGRRLLLRSVQLHDSGNYSCYRAGRPAGTVHLLVDVPPEEPQLSCFRKSPLSNVVCEWGPRSTPSLTTKAVLLVRKFQNSPAEDFQEPCQYSQESQKFSCQLAVPEGDSSFYIVSMCVASSVGSKFSKTQTFQGCGILQPDPPANITVTAVARNPRW LSVTWQDPHSWNSSFYRLRFELRYRAERSKTFTTWMVKDLQHHCVIHDAWSGLRHVVQLRAQEEFGQGEWSEWSPEAMGTPWTESRSPPPAENEVSTPMQLTTNKDDDNILFRDSANATSLPVQDSSSVPLPTFLVAGGSLAFGTLLCIAIVLRFKKTWKLRALKEGKTSMHPPYSLGQLVPERPRPTPVLVPLISPPVSPSSLGSDNTSSSHNRPDARDPRSPYDISNTDYFFPR.
[0043] The term "antibody" refers to each V H and V L "Antibody" refers to a protein that binds to another molecule (antigen) via heavy and light chain variable domains, as described above. "Antibody" refers to any polyclonal or monoclonal immunoglobulin molecule, or a mixture thereof, such as IgM, IgG, IgA, IgE, or IgD. Antibodies may belong to any antibody class or subclass. Examples of IgG subclasses include IgG 1 , IgG 2 , IgG 3 and IgG 4 is.
[0044] The term "monoclonal" when used with respect to antibodies means an antibody that is based on, obtained from, or derived from a single clone, including any eukaryotic, prokaryotic, or phage clone. A "monoclonal" antibody is thus defined herein structurally, and not by the method by which it is produced.
[0045] The antibody includes antibodies having kappa or lambda light chain sequences, including full-length sequences like naturally occurring antibodies, mixtures thereof (i.e., fusions of kappa and lambda chain sequences), and subsequences / fragments thereof. Naturally occurring antibody molecules contain two kappa light chains and two lambda light chains. The main difference between kappa and lambda light chains is in the sequence of the constant region.
[0046] An antibody comprising or consisting of a heavy (H) chain and / or a light (L) chain or a fragment of a heavy (H) or light (L) chain includes a single H or L chain or a single H or L chain fragment, or multiple (2, 3, 4 or more) heavy (H) and / or light (L) chains, or multiple fragments of heavy (H) and / or light (L) chains. A fusion polypeptide (FynomAb) comprising the heavy (H) and / or light (L) chains of an antibody or fragment does not necessarily contain two heavy (H) chains and two light (L) chains, and is therefore referred to herein as a fusion polypeptide (FynomAb). An antibody or fragment thereof may be in an oligomeric (higher order or valency) form with another antibody, fragment thereof, heavy (H) chain, light (L) chain, or polypeptide different from the heavy (H) or light (L) chain of the antibody, such as a trimer, tetramer, pentamer, hexamer, heptamer, etc.
[0047] As used herein, the term "bispecific" and grammatical variations thereof, when used in reference to a fusion polypeptide sequence, means that the fusion polypeptide binds to two different targets. Polypeptide targets are considered different when they have different amino acid sequences. The bispecific fusion polypeptides of the present disclosure bind to interleukin-6 receptor (IL-6R) and interleukin-17a (IL-17a).
[0048] As used herein, the terms "fusion" or "chimeric" and grammatical variations thereof, when used in reference to a sequence, mean that the sequence contains one or more portions based on, derived from, obtained from, or isolated from two or more different proteins. That is, for example, one portion of the sequence may be based on one particular protein and another portion of the sequence may be based on a different particular protein. Thus, a fusion or chimeric polypeptide is a molecule in which different portions of the polypeptide are derived from different proteins.
[0049] The terms "protein," "polypeptide," and "peptide" are used interchangeably herein and refer to two or more amino acids, or "residues," covalently linked by an amide bond or equivalent bond. Amino acid sequences may be joined by non-natural or non-amide chemical bonds, including, for example, those formed using glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, or N,N'-dicyclohexylcarbodiimide (DCC). Non-amide bonds include, for example, ketomethylene, aminomethylene, olefins, ethers, thioethers, and the like (see, e.g., Spatola in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp. 267-357 (1983), "Peptide and Backbone Modifications," Marcel Decker, NY).
[0050] The bispecific fusion polypeptides of the present disclosure are fusion polypeptides (FynomAbs) that contain a fynomeric sequence that binds to interleukin-17a (IL-17a) and forms a complex with an antibody or subsequence of an antibody that binds to the interleukin-6 receptor (IL-6R). The fynomeric sequence may be attached to the amino or carboxy terminus of the IL-6R-binding antibody or subsequence. Similarly, either the amino or carboxy terminus of the fynomeric sequence may be attached to the amino or carboxy terminus of the antibody or subsequence. Multiple fynomeric sequences may be attached to multiple amino or carboxy termini of an antibody or subsequence via the amino or carboxy termini of the fynomeric sequence. In addition, end-to-end fynomeric sequences or a series of multiple fynomeric sequences may be attached to the amino or carboxy terminus of an antibody or subsequence.
[0051] The terms "bind" or "binding," when used in reference to a Fynomer, antibody or subsequence thereof, or fusion polypeptide (e.g., FynomAb), mean that the Fynomer, antibody or subsequence thereof, or fusion polypeptide specifically binds to all or a portion of a target. The Fynomer, antibody or subsequence thereof, or fusion polypeptide (FynomAb) specifically or selectively binds to IL-17a and / or IL-6R protein, selective for an epitope or antigenic determinant present on the IL-17a or IL-6R protein. Selective binding refers to binding to a target protein. Binding to a non-target protein that does not significantly interfere with binding to the target protein is also considered selective. Selective binding can be distinguished from non-selective binding using specificity, affinity, and competitive and non-competitive binding assays described herein or known in the art.
[0052] A Fynomer / antibody fusion polypeptide (FynomAb) may have the same or substantially the same binding specificity as the exemplified Fynomer, antibody, and subsequence thereof. The affinity for the target may be higher or lower than that of a reference Fynomer, antibody, or subsequence thereof, or a reference Fynomer / antibody fusion polypeptide (FynomAb). A given FynomAb may or may not detectably compete for or inhibit binding to a region of the target that does not interfere with another Fynomer, antibody, subsequence, or FynomAb.
[0053] A Fynomer / antibody fusion polypeptide (FynomAb) that specifically binds to all or part of a sequence on a target may also bind to other proteins that have the same or similar epitope as the target. A fusion polypeptide (FynomAb) that binds to the same sequence or epitope or part of an epitope may have a higher or lower relative binding affinity or specificity for the target than a reference Fynomer or antibody or their fusion.
[0054] Fynomers and antibodies, as well as fusion polypeptides (FynomAbs), also include sequences that compete for binding to their respective targets. Thus, for example, a given Fynomer, antibody, subsequence, or FynomAb may inhibit or compete with the binding of another Fynomer, antibody, subsequence, or FynomAb for binding to IL-17a and / or IL-6R. In certain non-limiting examples, a Fynomer, antibody, subsequence, or FynomAb may inhibit the binding of any of COVA801-808 to IL-17a and / or IL-6R by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% or more. Thus, the finomer may compete with the binding of any of the finomers set forth in SEQ ID NOs: 1 to 7 for binding to IL-17a (e.g., glycosylated IL-17a), and the antibody or subsequence thereof may compete with the binding of antibodies including SEQ ID NOs: 8 and 9 for binding to IL-6R.
[0055] FynomAbs can include FynomAbs or subsequences thereof or fusion polypeptides (FynomAbs) that have higher or lower affinity for a target (e.g., IL-17a or IL-6R) than a reference FynomAb or antibody or subsequence thereof or fusion polypeptide (FynomAb). For example, FynomAbs of the present disclosure can be those that have higher or lower affinity for IL-17a (e.g., glycosylated IL-17a) and / or IL-6R, as well as sequences that have at least 60% or more (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the Fynomeric sequences set forth in SEQ ID NOs: 1-7, or sequences that have at least 60% or more (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) identity to the heavy or light chain variable region sequences set forth in SEQ ID NO: 8 or 9. In certain embodiments, the fusion polypeptide (FynomAb) has a higher affinity for glycosylated IL-17a than the Fynomeric sequence set forth in SEQ ID NO: 1.
[0056] Thus, FynomAbs comprise sequences that have the same or different binding affinities for IL-17a (e.g., glycosylated IL-17a) and / or IL-6R. For example, a FynomAb can have an affinity that is 2-5, 5-10, 10-100, 100-1000, or 1000-10,000 times higher or lower than another FynomAb, e.g., COVA801-808, or any number or range of numbers within such ranges for a target (e.g., glycosylated IL-17a and / or IL-6R).
[0057] The binding affinity is expressed as the binding rate (K a ) and dissociation rate (K d The equilibrium affinity constant, KD, can be determined by K a / K d A phenomer or antibody that has the same binding affinity as another phenomer or antibody will have a dissociation constant (K d) is within about 1 to 10 fold (1-10 fold higher affinity or 1-10 fold lower affinity than a reference antibody or molecule, or any numerical value or range or values within such range). An exemplary affinity for a target antigen (e.g., IL-17a, e.g., glycosylated IL-17a, or IL-6R) is 5x10 -2 M, 10 -2 M, 5x10 -3 M, 10 -3 M, 5x10 -4 M, 10 -4 M, 5x10 -5 M, 10 -5 M, 5x10 -6 M, 10 -6 M, 5x10 -7 M, 10 -7 M, 5x10 -8 M, 10 -8 M, 5x10 -9 M, 10 -9 M, 5x10 -10 M, 10 -10 M, 5x10 -11 M, 10 -11 M, 5x10 -12 M, 10 -12 M, 5x10 -13 M, 10 -13 M, 5x10 -14 M, 10 -14 M, 5x10 -15 M, and 10 -15 Dissociation constant (K d Generally, the binding affinity (K d ) is 10 -7 M, 5x10 -8 M, 10 -8 M, 5x10 -9 M, 10 -9 M, 5x10 -10 M, 10 -10 M, 5x10 -11 M, 10 -11 M, 5x10 -12 M, or 10 -12 It may be less than M.
[0058] More specifically, the affinity of the FynomAb for a typical target antigen, IL-17a (e.g., glycosylated IL-17a), is about 0.01 nM to about 0.50 nM, or about 0.02 nM to about 0.40 nM. More specifically, the affinity of the antibody or subsequence thereof or fusion polypeptide (FynomAb) for a typical target antigen, IL-6R, is about 0.20 nM to about 1.25 nM, or about 0.30 nM to about 1.10 nM.
[0059] Fynomers and antibodies, as well as fusion polypeptides (FynomAbs), can include those that have at least some "activity" or "function" of a fusion containing a reference Fynomer, antibody, or FynomAb. The activity or function can include binding affinity (e.g., K d , KD), binding specificity, or activity, e.g., antagonist activity. The term "at least a portion" means that a FynomAb, antibody, or fusion polypeptide (FynomAb) retains at least a measurable or detectable amount of the activity or function of a reference FynomAb, antibody, or fusion polypeptide (FynomAb) exemplified herein. A FynomAb, antibody, or fusion polypeptide (FynomAb) may have greater or less activity or function than the reference FynomAb, antibody, or fusion polypeptide (FynomAb).
[0060] The Fynomer, antibody, or fusion polypeptide (FynomAb) may have antagonist or agonist activity or function. In one embodiment, the Fynomer, antibody, or fusion polypeptide (FynomAb) may have antagonist or agonist activity or function against IL-17a and / or IL-6R.
[0061] An "antagonist" can decrease, reduce, or inhibit one or more activities of a target molecule, e.g., signaling by IL-17a or IL-6R. Antagonists can interfere with the binding of IL-17a to its receptor or IL-6R to its ligand, disabling or killing cells activated by the ligand and / or interfering with signaling. Antagonists can completely prevent, substantially reduce, diminish, or inhibit the interaction of the ligand with the receptor.
[0062] An "agonist" is capable of increasing, inducing, or activating one or more activities of a target molecule, such as signaling by IL-17a or IL-6R. An agonist may increase, induce, or promote binding of the receptor to a ligand (or vice versa), or may act directly on the receptor or ligand to increase, induce, promote, or activate signaling.
[0063] Fynomers, antibodies, or fusion polypeptides (FynomAbs) that have the activity or function of a reference FynomAb can be identified by various methods described herein or known in the art. For example, binding assays to IL-17a (e.g., glycosylated IL-17a) or IL-6R on plates (ELISA) or on cells (cell-based ELISA) can be used. Specific inhibition of binding to IL-17a or IL-6R can be used as a measure of binding specificity and affinity. Exemplary assays can be those that can determine a function or activity, such as IL-17a or IL-6R activity, e.g., signaling activity.
[0064] As described herein, an antibody, Fynomer, or fusion polypeptide (FynomAb) may have one or more modifications within a reference sequence. Non-limiting examples of modifications may include one or more amino acid substitutions (e.g., 1-3, 3-5, 5-10, or more residues), additions (e.g., 1-3, 3-5, 5-10, or more residues), or deletions (e.g., subsequences or fragments) of the reference Fynomer, reference antibody (heavy or light chain), or fusion polypeptide (FynomAb). In certain embodiments, a modified Fynomer, antibody, or fusion polypeptide (FynomAb) retains at least part of the function or activity of the unmodified reference antibody, Fynomer, or fusion polypeptide (FynomAb), e.g., binding affinity (e.g., K) to IL-6R or IL-17a (e.g., glycosylated IL-17a) in vitro or in vivo, or in or on cells (e.g., cultured), or in vivo. d , KD) or retain binding specificity.
[0065] A Fynomer, antibody or subsequence thereof, or FynomAb can have at least partial sequence identity (less than 100%) with a parent or reference Fynomer, or antibody heavy or light chain variable region sequence, or fusion polypeptide (FynomAb), respectively, described herein. For example, the Fynomers (SEQ ID NOS: 1-7) and / or the heavy and light chain sequences of tocilizumab (SEQ ID NOS: 8-9) described herein. The percent identity of such Fynomers, antibodies, subsequences thereof, or fusion polypeptides (FynomAbs) can be as little as 60% or higher (e.g., 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%). The percent identity can be over the entire sequence set forth in SEQ ID NOS: 1-9, or over a continuous region or portion within any of SEQ ID NOS: 1-9. In one embodiment, the length of sequences sharing percent identity is 5 or more contiguous amino acids, e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous amino acids. In another embodiment, the length of sequences sharing percent identity is 20 or more contiguous amino acids, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 contiguous amino acids. In a further embodiment, the length of sequences sharing percent identity is 35 or more contiguous amino acids, e.g., 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 45, 47, 48, 49, or 50 contiguous amino acids. In yet another embodiment, the length of sequences sharing percent identity is 50 or more contiguous amino acids, for example, 50-55, 55-60, 60-65, 65-70, 70-75, 75-80, 80-85, 85-90, 90-95, 95-100 or 100-110 contiguous amino acids.
[0066] The bispecific fusion polypeptide can be a fusion polypeptide (FynomAb) having either a Fynomer sequence, the heavy or light chain variable region of an antibody set forth in SEQ ID NOs: 1-9, or a sequence containing one or more amino acid substitutions in the sequence of SEQ ID NOs: 1-9. In one embodiment, the substituted Fynomer and / or antibody heavy and / or light chain sequences can retain at least some binding affinity and / or specificity for target IL-17a (e.g., glycosylated IL-17a) and / or IL-6R.
[0067] In one embodiment, the Fynomer sequence can have 1-15, 1-12, 1-8, 1-5, 1-3 or fewer (e.g., 1 or 2) amino acid substitutions. In particular, the substitutions can be of amino acids within any of the Fynomer sequences (SEQ ID NOs: 1-7).
[0068] In another embodiment, no substitutions are made in the motifs GVTLFVALYDY, DLSFHKGEKFQIL, STHEY, STHEYE, STHEYED, WWEAR, DWWEAR, SLTTGETGYIPSNYVAPVDSIQ, or QILSTHEYEDWWEAR in the finomer sequence. In another embodiment, the E-amino acid residue located immediately after the src loop sequence in the finomer sequence is not substituted.
[0069] An antibody or fusion polypeptide (FynomAb) may have one or more substitutions in the constant or variable (e.g., hypervariable, such as CDR or FR) regions. One or several amino acid substitutions in the constant or variable regions may be tolerated. Non-conservative substitutions of multiple amino acids in one or more hypervariable regions may affect the binding activity and specificity of the antibody or fusion polypeptide (FynomAb).
[0070] Thus, modifications can include deletion of small and large regions of the amino acid sequence from the reference antibody, FynomAb, or fusion polypeptide (FynomAb). The deleted region can then be replaced with another amino acid sequence, if desired. The replaced sequence can be the same length as, longer than, or shorter than the deleted region.
[0071] A specific example of antibody or fusion polypeptide (FynomAb) modification is alteration to have a different isotype or subclass, for example, by substitution of the heavy or light chain constant region. Altering the Ig subclass can result in altered or improved function or activity (e.g., anti-IL-6R activity, stability). Another example is alteration that results in improved properties, such as increased serum stability and / or half-life in vivo or in PK (e.g., as described in Antibody Engineering Vol. 1, Konterman R and Duebel S, eds., 2010, Springer, WO2006 / 130834 and Horton et al., Cancer Res 68:8049 (2008)). Non-limiting examples of substitutions in the Fc include I253A, H310A, H435R, H435Q, G236R, L328R, S239D, and I332E. Non-limiting examples of substitutions in IgG1 may be at residues 238, 252, 253, 254, 255, 256, 265, 272, 289, 288, 303, 305, 307, 309, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 386, 388, 400, 413, 415, 424, 433, 434, 435, 439 and / or 477 of the Fc region.
[0072] In one embodiment, the heavy or light chain CDRs (CDR1, CDR2, or CDR3) or FRs may have 1-15, 1-12, 1-8, 1-5, 1-3, or fewer (e.g., 1 or 2) amino acid substitutions. In one embodiment, the substitutions within the variable region sequence may be conservative amino acid substitutions, e.g., within a CDR or FR. In another embodiment, the substitutions within the variable region sequence may not be within a CDR. In another embodiment, the substitutions may be within a FR. In another embodiment, the substitutions within the variable region sequence may not be within a FR. Examples of heavy and light chain variable region CDR sequences that confer IL-6R binding are set forth in SEQ ID NOs: 8 and 9, i.e., heavy chain variable region CDRs 1-3 are SDHAWS (SEQ ID NO: 44); YISSYSGITTYNPSLKS (SEQ ID NO: 45); and SLARTTAMDY (SEQ ID NO: 46), and light chain variable region CDRs 1-3 are RASQDISSYLN (SEQ ID NO: 47); YTSRLHS (SEQ ID NO: 48); and QQGNTLPYT (SEQ ID NO: 49).
[0073] Structural determinants that contribute to antigen binding by antibodies, such as complementarity-determining regions (CDRs) and framework regions (FRs) within hypervariable regions, are known in the art. The location, structure, and function of additional regions, such as D and J regions, are also known. An antibody, subsequence thereof, or fusion polypeptide (FynomAb) that binds to a given target (e.g., IL-6R) will generally have one or more CDR and FR sequences that have sufficient sequence identity with a heavy or light chain sequence that binds to IL-6R so as to retain at least some function or IL-6R-binding activity. For example, as exemplified herein, one or more CDRs of the heavy or light chain sequences set forth in SEQ ID NOS: 8-9 can retain at least some function or activity of an antibody with binding specificity for IL-6R.
[0074] Regional variability analysis can be used to predict the effect of specific substitutions in complementarity-determining regions (CDRs) and framework regions (FRs) (Shapiro et al., J Immunol. 163:259 (1999)). In summary, sequence comparisons reveal a mutation hierarchy among di- and tri-nucleotide sequences located within Ig intron DNA, predicting regions of higher or lower variability. Quantitative structure-activity relationships (QSAR) can be used to distinguish the nature of antibody recognition domains and, therefore, to identify amino acids involved in ligand binding. QSAR-based predictive models can then be used to predict the effect of substitutions (mutations). For example, the effect of a mutation on the association and dissociation rates of an antibody interacting with its antigen can be determined by measuring both kinetics (K a and K. d ) constants, which can then be used to predict the effects of other mutations on antibodies (De Genst et al., J. Biol. Chem. 277:29897 (2002)). Thus, one skilled in the art can use such analyses to predict potential amino acid substitutions that will result in antibodies or subsequences that retain at least some activity or function of the unsubstituted antibody, subsequence, or fusion polypeptide (FynomAb), e.g., retain at least some binding to IL-6R.
[0075] The effect of a given substitution can be assayed to identify antibodies and fusion polypeptides (FynomAbs) that retain at least some of the binding activity, specificity, or antibody function or activity of an unsubstituted reference antibody or fusion polypeptide (FynomAb). For example, amino acid substitutions, additions, deletions, or insertions within the hypervariable region of an antibody or fusion polypeptide (FynomAb) that binds to IL-6R can be assayed for IL-6R binding activity or binding specificity. Thus, antibodies and fusion polypeptides (FynomAbs) with amino acid substitutions, as well as additions, deletions, and insertions, are encompassed that at least some of the function or activity, such as binding affinity, binding specificity, or ability to bind to a cellular target (e.g., IL-6R) in vitro (e.g., in culture) or in vivo, are at least partially retained.
[0076] The term "identity" and grammatical variations thereof mean that two or more compared objects are the same. Thus, when two amino acid sequences are identical, they have the same amino acid sequence. Identity may exist over a defined portion (region or domain) of the sequence. A "portion, region, or domain" of homology or identity means that a portion of two or more referenced entities shares homology or is the same. Thus, when two sequences are identical over one or more sequence regions, they share identity in these regions.
[0077] Amino acid substitutions can be conservative or non-conservative. A "conservative substitution" refers to the replacement of one amino acid with a biologically, chemically, or structurally similar residue. Biologically similar means that the substitution corresponds to biological activity, e.g., retains binding to IL-17a or IL-6R. Structurally similar means that the amino acids have side chains of similar length, e.g., alanine, glycine, and serine, or similar size. Chemically similar means that the residues have the same charge or are both hydrophilic or hydrophobic. Specific, non-limiting examples include the substitution of one hydrophobic residue for another, e.g., isoleucine, valine, leucine, or methionine, or the substitution of one polar residue for another, e.g., arginine for lysine, glutamine for aspartic acid, or glutamine for asparagine, serine for threonine, etc.
[0078] Amino acid substitutions may be with the same amino acid, except that a naturally occurring L-amino acid may be substituted with a D-amino acid. Thus, modifications include substituting one or more D-amino acids for an L-amino acid, or substituting a mixture of D-amino acids for an L-amino acid.
[0079] The degree of identity between two sequences can be determined using computer programs and mathematical algorithms known in the art. Such algorithms that calculate the percent sequence identity (homology) generally account for sequence gaps and mismatches over the comparison region or portion. For example, the BLAST (e.g., BLAST 2.0) search algorithm (see, e.g., Altschul et al., J. Mol. Biol. 215:403 (1990), publicly available from NCBI) has the following exemplary search parameters: Mismatch -2; gap open 5; gap extension 2. For polypeptide sequence comparison, the BLASTP algorithm is generally used in combination with a scoring matrix such as PAM100, PAM250, BLOSUM62, or BLOSUM50. FASTA (e.g., FASTA2 and FASTA3) and SSEARCH sequence comparison programs are also used to quantify the degree of identity (Pearson et al., Proc. Natl. Acad. Sci. USA 85:2444 (1988); Pearson, Methods Mol. Biol. 132:185 (2000); and Smith et al., J. Mol. Biol. 147:195 (1981)). Programs for quantifying protein structural similarity using Delaunay-based topology mapping have also been developed (Bostick et al., Biochem. Biophys. Res. Commun. 304:320 (2003)).
[0080] Modifications include alterations to the activity or function (e.g., affinity or specific binding to IL-17a or IL-6R) of the reference composition. Modified Fynomers, antibodies, and fusion polypeptides (FynomAbs) with altered properties, such as increased binding affinity, increased antagonist activity, etc., can be produced using methods known in the art. For example, affinity maturation techniques can be used to improve antibody binding affinity (US 2004 / 0162413 A1; U.S. Patent Nos. 6,656,467, 6,531,580, 6,590,079, and 5,955,358; Fiedler et al., Protein Eng. 15:931 (2002); Pancook et al., Hybrid. Hybridomics 20:383 (2001); Daugherty et al., Protein Eng. 11:825 (1998); Wu et al., Proc. Nat'l Acad. Sci. USA 95:6037 (1998); and Osbourn et al., Immunotechnology 2:181 (1996)).
[0081] Fynomers, antibodies, and fusion polypeptides (FynomAbs) include subsequences (e.g., fragments) and modified forms (e.g., sequence variants) described herein. A Fynomer subsequence refers to a functional fragment or subsequence of a reference Fynomer, e.g., a sequence having a deletion of one or more amino acids of any of SEQ ID NOS: 1-7. An "antibody" subsequence refers to a functional fragment or subsequence of an immunoglobulin. Non-limiting examples of antibody subsequences include Fab, Fab', F(ab'), and F(ab'). 2 , Fv, Fd, single-chain Fv (scFv), disulfide-linked Fv (sdFv), V L , V H , diabody ((V L -V H ) 2 Or (V H -V L ) 2 ), triabody (trivalent antibody), tetrabody (tetravalent antibody), minibody ((scF V -CH 3) 2 ), IgGdeltaCH2, scFv-Fc or (scFv) 2 -Fc fragments may be included. In particular embodiments, Fab, Fab', F(ab') 2 , Fv, Fd, single-chain Fv (scFv), disulfide-linked Fv (sdFv), V L , V H , diabody ((V L -V H ) 2 Or (V H -V L ) 2 ), triabody (trivalent antibody), tetrabody (tetravalent antibody), minibody ((scF V -C H 3) 2 ), IgGdeltaCH2, scFv-Fc and (scFv) 2 -Fc subsequences. Such subsequences and fusion polypeptides (FynomAbs) may have at least a portion of the sequence set forth in SEQ ID NO: 8 or 9 (e.g., one or more CDRs (CDR1-CDR3 of the heavy or light chain variable region sequence) and / or FRs of SEQ ID NO: 8-9).
[0082] In certain embodiments, the subsequence has substantially the same or the same IL-17a or IL-6R binding affinity or IL-17a or IL-6R binding specificity, or one or more functions or activities of an IL-17a-binding fibronectin or IL-6R-binding antibody in vitro or in vivo, or in a cell in vitro or in vivo. The terms "functional subsequence" and "functional fragment," when referring to a fibronectin, antibody, or fusion polypeptide (FynomAb), refer to a portion of a fibronectin or antibody or fusion polypeptide (FynomAb) that retains at least a portion of one or more functions or activities of the intact, reference fibronectin or antibody or fusion polypeptide (FynomAb), e.g., a fibronectin that binds IL-17a, an antibody that binds IL-6R, or a fusion polypeptide (FynomAb) that binds IL-17a and IL-6R.
[0083] Antibody subsequences, including single-chain antibodies, can include all or a portion of a heavy or light chain variable region (e.g., CDR1, CDR2, or CDR3) alone or in combination with all or a portion of one or more of the following: hinge region, CH1, CH2, and CH3 domains. Also included are antigen-binding subsequences of any combination of heavy or light chain variable regions (e.g., CDR1, CDR2, or CDR3) that include hinge region, CH1, CH2, and CH3 domains.
[0084] A further modification of the bispecific fusion polypeptide (FynomAb) is addition (derivative) / insertion. An example of addition may include the addition of a polypeptide sequence, in which an amino acid sequence having one or more molecules not normally present in the reference native (wild-type) sequence is covalently linked to the sequence. A specific example of a peptide addition is the attachment (covalent or non-covalent) of a second heterologous sequence, i.e., a heterologous functional domain, that confers a different or complementary function to the bispecific fusion polypeptide (FynomAb). Thus, the bispecific fusion polypeptide (FynomAb) may contain heterologous domains, i.e., heterologous functional domains, that confer different functions. For example, the Fc region may be a chimera containing portions of human IgG1 and IgG3 Fc regions.
[0085] The heterologous functional domains that can be used are not limited to amino acid residues or domains. Thus, heterologous functional domains can be composed of any of a variety of different types of small or large functional moieties. Such moieties can include nucleic acids, peptides, carbohydrates, lipids, small organic molecules / compounds, such as drugs (e.g., anti-proliferative agents), metals (gold, silver), or radioisotopes. Thus, in another aspect, the present disclosure provides detectably labeled FynomAbs.
[0086] The bispecific fusion polypeptide FynomAb may have additions or may be derivatives. For example, the polypeptide may contain sugar residues, phosphate groups, ubiquitin, fatty acids, or lipids, or may be glycosylated, phosphorylated, acetylated, amidated, or formylated. The polypeptide may be derivatized with a protecting group / blocking group or any of a number of chemical modifying groups. The modification of the polypeptide may also be an intramolecular or intermolecular disulfide bond.
[0087] A linker, such as an amino acid or peptidomimetic sequence, may be inserted between the phenomer and / or antibody sequence and the heterologous functional domain so that the two entities maintain, at least in part, different functions or activities. In one embodiment, the phenomer domain is inserted into a heavy (H) or light (L) chain at an amino acid (NH) of the heavy (H) or light (L) chain. 2 The linker is attached immediately after the last amino acid of the carboxy (C)-terminus or carboxy (C)-terminus. The linker may have one or more properties, including a flexible conformation, an inability to form regular secondary structures, or hydrophobic or charged properties that may promote or interact with interdomain binding. Examples of amino acids commonly found in flexible protein regions include Gly, Asn, and Ser. Other near-neutral amino acids, such as Thr and Ala, can also be used in the linker sequence. The length of the linker sequence can be varied without significantly affecting the function or activity of the fusion protein (see, e.g., U.S. Patent No. 6,087,329). In certain embodiments, the finomer and the heavy or light chain of the antibody are linked by a peptide sequence having about 1 to 25 amino acid residues.
[0088] Examples of linkers may also include chemical moieties and coupling agents such as sulfo-succinimidyl derivatives (sulfo-SMCC, sulfo-SMPB), disuccinimidyl suberate (DSS), disuccinimidyl glutarate (DSG), and disuccinimidyl tartrate (DST). Linkers may also include linear carbon chains, e.g., C Nwhere N=1-100 carbon atoms, e.g., C, CC, CCC, CCCC, CCCCC, CCCCCC, CCCCCCCC, CCCCCCCC.
[0089] It is understood that a polymerase, antibody, or subsequence may have multiple (e.g., two or more) mutations, modifications, or labels. For example, the heavy or light chain sequences of an antibody may be conjugated with biotin so that they can be detected with avidin, and the heavy or light chain sequences may be conjugated with I to provide a detectable signal. 125 Other permutations and possibilities will be readily apparent to one of ordinary skill in the art and are considered to be within the scope of the present disclosure.
[0090] Examples of antibodies and fusion polypeptides (FynomAb) can include mammalian sequences, human sequences, humanized sequences, and primate sequences. With respect to antibodies, the term "human" means that the amino acid sequence is fully derived from a human. Thus, a "human antibody" refers to an antibody having human immunoglobulin amino acid sequences, i.e., an antibody having human heavy and light chain variable and constant regions that specifically bind to a target. Thus, a "human IL-6R antibody" or a "human anti-IL-6R antibody" refers to an antibody having human immunoglobulin amino acid sequences and binds to IL-6R. That is, all of the antibody amino acids are human or can be present in a human antibody. Thus, for example, a non-human antibody can be made fully human by replacing non-human amino acid residues with amino acid residues that can be present in a human antibody. The amino acid residues present in human antibodies, CDR region maps, and human antibody consensus residues are known in the art (e.g., Kabat, Sequences of Proteins of Immunological Interest, 4 th Ed. US Department of Health and Human Services. Public Health Service (1987); and Chothia and Lesk J. Mol. Biol. 186:651 (1987)). H Human VIII sequence based on inspection HConsensus sequence of subgroup III and human V based on survey of 30 known human κI sequences L The consensus sequence for kappa chain subgroup I is described in Padlan Mol. Immunol. 31:169 (1994); and Padlan Mol. Immunol. 28:489 (1991). Thus, human antibodies include antibodies in which one or more amino acid residues are substituted with one or more amino acids present in another human antibody.
[0091] The term "humanized" when used with respect to an antibody means that the amino acid sequence of the antibody contains non-human amino acid residues (e.g., mouse, rat, goat, rabbit, non-human primate, etc.) in one or more complementarity-determining regions (CDRs) that specifically bind to a desired target (e.g., IL-6R) in an acceptor human immunoglobulin molecule, as well as one or more human amino acid residues in the Fv framework regions (FRs), which are the amino acid residues adjacent to the CDRs. Residues in the human framework regions of the immunoglobulin may be replaced with corresponding non-human residues. Thus, residues in the human framework regions may be substituted with corresponding residues from the non-human CDR donor antibody to alter, e.g., generally improve, antigen affinity or specificity. Furthermore, a humanized antibody may contain residues that are found neither in the human antibody nor in the donor CDR or framework sequences. For example, framework substitutions at particular positions not found in the human antibody or donor non-human antibody may be predicted to improve the binding affinity or specificity of the human antibody at that position.
[0092] Antibody framework and CDR replacements based on molecular modeling are known in the art, for example, by modeling the interactions of CDR and framework residues to identify framework residues important for antigen binding and by sequence comparison to identify unusual framework residues at specific positions (see, e.g., U.S. Pat. No. 5,585,089; and Riechmann et al., Nature 332:323 (1988)). Antibodies that are referred to as "primatized" are within the meaning of "humanized" as used herein, except that the acceptor human immunoglobulin molecule and framework region amino acid residues may be any primate amino acid residue (e.g., monkey, gibbon, gorilla, chimpanzee, orangutan, macaque) in addition to any human residues.
[0093] The term "isolated," when used in reference to a component (e.g., a Fynomer, antibody, heavy or light chain sequence, fusion polypeptide (FynomAb), etc.), means that the component has been produced by the hand of man or has been completely or at least partially separated from its naturally occurring in vivo environment. Generally, isolated components are substantially free of one or more substances with which they are normally associated in nature, e.g., one or more proteins, nucleic acids, lipids, carbohydrates, cellular membranes. The term "isolated" does not exclude distinct physical forms of the component, such as multimers / oligomers, mutants, modified or derived forms, or forms expressed in a host cell produced by man. The term "isolated" also does not exclude compositions or formulations containing components produced by the hand of man.
[0094] An "isolated" component may also be "purified" when it is free from most or all of the materials with which it is normally associated in nature. Thus, a substantially pure or purified isolated fusion polypeptide (FynomAb) does not contain a polypeptide or multiple polynucleotides present among millions of other sequences, e.g., a polypeptide library or nucleic acid in a genomic or cDNA library. A "purified" component may be combined with one or more other molecules. Thus, "purified" does not exclude combinations of components, such as combinations of FynomAbs (multiple FynomAbs), and FynomAbs in combination with other active agents or drugs.
[0095] The bispecific fusion polypeptide can be produced by the method described in WO 2015 / 141862 (Patent Document 1).
[0096] Measurement of Biomarker Molecule Levels and Prediction of Efficacy In the Examples described below, it was found that treatment of SSc by inhibiting IL-6R and IL-17a may be effective for SSc patients with high blood levels of at least one protein selected from IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1. Therefore, the efficacy of treatment of SSc with a bispecific fusion polypeptide against IL-6R and IL-17a can be predicted based on the levels of biomarker molecules in a sample collected from a subject.
[0097] The biomarker molecule is at least one biomarker molecule selected from IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1. For predicting efficacy, a single biomarker molecule may be used, or multiple biomarker molecules may be used in any combination. That is, any one, two, three, four, five, six, or seven biomarker molecules, or all eight biomarker molecules selected from IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1 may be used.
[0098] In one aspect, the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1, and optionally IL-6. In one aspect, the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, and PLAUR, and optionally IL-6.
[0099] IL-6 is an abbreviation for interleukin-6. The amino acid sequences of IL-6 derived from various species are readily available from publicly known databases. A representative amino acid sequence of human IL-6 is registered as P05231 (Uniprot ID) (SEQ ID NO: 50). In the present disclosure, IL-6 includes its naturally occurring allelic products.
[0100] GDF15 is an abbreviation for growth differentiation factor 15. The amino acid sequences of GDF15 derived from various biological species are readily available from publicly known databases. A representative amino acid sequence of human GDF15 is registered as Q99988 (Uniprot ID) (SEQ ID NO: 51). In the present disclosure, GDF15 includes its naturally occurring allelic products.
[0101] LTBP2 is an abbreviation for latent transforming growth factor beta-binding protein 2. The amino acid sequences of LTBP2 derived from various biological species are readily available from publicly known databases. A representative amino acid sequence of human LTBP2 is registered as Q14767 (Uniprot ID) (SEQ ID NO: 52). In the present disclosure, LTBP2 includes its naturally occurring allelic products.
[0102] CCL7 is an abbreviation for C-C motif chemokine ligand 7. The amino acid sequences of CCL7 derived from various species are readily available from publicly known databases. A representative amino acid sequence of human CCL7 is registered as P80098 (Uniprot ID) (SEQ ID NO: 53). In the present disclosure, CCL7 includes its naturally occurring allelic products.
[0103] CHI3L1 is an abbreviation for chitinase-3-like protein 1. The amino acid sequences of CHI3L1 derived from various biological species are readily available from publicly known databases. A representative amino acid sequence of human CHI3L1 is registered as P36222 (Uniprot ID) (SEQ ID NO: 54). In the present disclosure, CHI3L1 includes products of its naturally occurring alleles.
[0104] EFEMP1 is an abbreviation for EGF-containing fibulin-like extracellular matrix protein 1. The amino acid sequences of EFEMP1 derived from various species are readily available from public databases. A representative amino acid sequence of human EFEMP1 is registered as Q12805 (Uniprot ID) (SEQ ID NO: 55). In the present disclosure, EFEMP1 includes products of its naturally occurring alleles.
[0105] PLAUR is an abbreviation for plasminogen activator urokinase receptor. The amino acid sequences of PLAUR derived from various species are readily available from public databases. A representative amino acid sequence of human PLAUR is registered as Q03405 (Uniprot ID) (SEQ ID NO: 56). In the present disclosure, PLAUR includes its naturally occurring allelic products.
[0106] SPON1 is an abbreviation for spondin 1. The amino acid sequences of SPON1 derived from various biological species are readily available from publicly known databases. A representative amino acid sequence of human SPON1 is registered as Q9HCB6 (Uniprot ID) (SEQ ID NO: 57). In the present disclosure, SPON1 includes products of its naturally occurring alleles.
[0107] In the present disclosure, a biomarker molecule may contain a sequence in which one or several amino acids have been deleted, substituted, or added to the original amino acid sequence, as long as its function is maintained. Here, "several" preferably means 2 to 7, more preferably 2 to 5, and most preferably 2 to 3 amino acids. Amino acid substitutions are preferably conservative substitutions between similar amino acid residues.
[0108] Furthermore, as long as the function of the biomarker molecule is maintained, the biomarker molecule may comprise an amino acid sequence that has an identity to the original amino acid sequence of at least about 60% or more, preferably about 70% or more, more preferably about 80% or more, even more preferably about 90% or more, particularly preferably about 95% or more, and most preferably about 97%, about 98%, or about 99% or more when calculated using BLAST or the like (for example, when using the default, i.e., initial condition, parameters of BLAST).
[0109] In this disclosure, a subject refers to an animal, generally a mammal, such as a human, a non-human primate (e.g., a monkey, a gibbon, a chimpanzee, an orangutan, or a macaque), a companion animal (e.g., a dog or a cat), a livestock animal (e.g., a horse, a cow, a goat, a sheep, or a pig), or an experimental animal (e.g., a mouse, a rat, a rabbit, or a guinea pig), preferably a human. Examples of subjects include animals in SSc models.
[0110] In the present disclosure, the subject suffers from systemic sclerosis (SSc). SSc is a disease characterized by fibrosis of the skin and various organs and impaired blood circulation due to vascular endothelial cell proliferation. SSc is classified into "diffuse systemic sclerosis" and "limited systemic sclerosis." In the former, skin sclerosis extends throughout the body and often progresses within 5 to 6 years from onset, and anti-Scl-70 antibodies (anti-topoisomerase I antibodies) and anti-RNA polymerase III antibodies can be detected as autoantibodies. In the latter, skin sclerosis is often limited to the fingers, with little or no progression, and anti-centromere antibodies and anti-U1-RNP antibodies can be detected as autoantibodies. In one embodiment, the subject suffers from diffuse systemic sclerosis. In another embodiment, the subject suffers from limited systemic sclerosis.
[0111] In one embodiment, the subject's blood IL-6 level is elevated compared to a value based on blood IL-6 levels measured in a group of healthy animals of the same species as the subject, and / or the subject's blood IL-17a level is elevated compared to a value based on blood IL-17a levels measured in a group of healthy animals of the same species as the subject. IL-6 is as described above. IL-17a is an abbreviation for interleukin-17a. The amino acid sequences of IL-17a derived from various biological species are readily available using publicly known databases. A representative amino acid sequence of human IL-17a is shown in SEQ ID NO: 10. In the present disclosure, IL-17a includes products of its naturally occurring alleles. Blood IL-6 and IL-17a levels can be measured using samples collected from a subject, as can the levels of biomarker molecules described below.
[0112] A healthy animal refers to an animal that is free from signs or symptoms of SSc. For example, an index value is set based on the IL-6 or IL-17a levels measured in a group of healthy animals and compared with the IL-6 or IL-17a level in the subject. The index value can be, for example, the mean value or the 55th, 60th, 65th, 70th, 75th, 80th, 85th, 90th, or 95th percentile value of the IL-6 or IL-17a levels measured in the group of healthy animals. The index value may be a value based on the levels measured for a group of healthy animals simultaneously with, in parallel with, before, or after the measurement of the IL-6 or IL-17a level in the subject, or may be a predetermined value.
[0113] The sample may be blood, plasma, or serum collected from a subject. Blood samples may be collected by conventional methods, for example, from a vein or artery. Plasma and serum samples may be prepared by appropriately treating the blood using methods well known to those skilled in the art. This treatment is not particularly limited and may be any clinically acceptable treatment. For example, addition of an anticoagulant, centrifugation, etc. may be performed. The sample may also be other body fluids collected from a subject, such as cerebrospinal fluid, saliva, nasal discharge, sputum, pleural effusion, or ascites. The collected sample may be stored at a low temperature during or after its preparation prior to use, for example, frozen. The collected sample may also be appropriately concentrated or diluted as needed before use.
[0114] The level of a biomarker molecule in a sample can be measured using a reagent that specifically binds to the biomarker molecule. The reagent that specifically binds to the biomarker molecule can be, for example, an antibody, RNA, DNA, polypeptide, or aptamer. These reagents can also be fragments, derivatives, or analogs of the biomarker molecule, as long as they are capable of specifically binding to the biomarker molecule.
[0115] For example, the level of a biomarker molecule in a sample can be measured by an immunological technique using an antibody that binds to it. Examples of immunological techniques include enzyme-linked immunosorbent assays (ELISAs, e.g., direct, indirect, sandwich, or competitive), immunochromatography, Western blotting, flow cytometry analysis, radioisotope immunoassays (RIAs), and proximity extension assays (PEA). In one embodiment, the level of a biomarker molecule in a sample is measured by the PEA method.
[0116] For antibodies, see the above description of the bispecific fusion polypeptide. Antibodies can be produced by existing general production methods using biomarker molecules or partial peptides thereof having antigenicity as immunogens. For example, polyclonal antibodies can be produced by immunizing animals with antigens, and monoclonal antibodies can be produced using hybridoma technology. Alternatively, commercially available antibodies can be used.
[0117] The reagent can be labeled with a detectable substance. Examples of detectable substances include radioisotopes, fluorescent labels, luminescent labels, bioluminescent labels, oligonucleotide labels, enzyme labels and biotin. Alternatively, the reagent can be unlabeled, and a labeled substance that recognizes the reagent, such as a secondary antibody, can be used.
[0118] The reagent may be bound to a suitable support. The support is not particularly limited as long as it can immobilize the reagent, and may be of any shape or material. Examples of such supports include membranes such as nylon membranes, beads, glass, plastic, and metal supports.
[0119] In this disclosure, "efficacy of a bispecific fusion polypeptide" refers to the likelihood that a bispecific fusion polypeptide will improve a subject's SSc or its symptoms. SSc includes diffuse cutaneous systemic sclerosis and localized cutaneous systemic sclerosis. Symptoms of SSc include skin symptoms such as Raynaud's phenomenon and sclerosis, pulmonary symptoms such as pulmonary fibrosis and pulmonary dysfunction, scleroderma renal crisis, reflux esophagitis, flexion contractures of the fingers, pulmonary hypertension, pericarditis, arrhythmias, arthralgia, myositis, pseudoileus, malabsorption, constipation, diarrhea, and right heart failure, particularly pulmonary symptoms.
[0120] A high probability that a subject's SSc or symptoms will improve is referred to as "effective," and can also be expressed as "responsive," "high probability of response," "eligible for treatment," etc. A low probability that a subject will improve is referred to as "ineffective," and can also be expressed as "not responsive," "low probability of response," "not eligible for treatment," etc.
[0121] In the present disclosure, "amelioration" of SSc or a symptom thereof means a detectable or measurable improvement in a subject's SSc or symptom thereof. Detectable or measurable improvement includes subjectively or objectively reducing, lowering, inhibiting, suppressing, limiting, or controlling the occurrence, frequency, severity, progression, or duration of SSc or a symptom thereof, and reversing SSc or a symptom thereof. Improvement of SSc or a symptom thereof does not require complete elimination of SSc or a symptom thereof. Improvement of SSc or a symptom thereof includes gradual improvement in a subject's SSc or a symptom thereof, as well as partial reduction, lowering, inhibiting, suppressing, limiting, or controlling the occurrence, frequency, severity, progression, or duration of SSc or a symptom thereof over short or long periods (hours, days, weeks, or months).
[0122] For example, if the level of a biomarker molecule in a sample taken from a subject is high compared to a cutoff value for the biomarker molecule, it is predicted that the bispecific fusion polypeptide will be effective in treating SSc or a symptom thereof in the subject, and if the level of the biomarker molecule is low compared to the cutoff value, it is predicted that the bispecific fusion polypeptide will not be effective in treating SSc or a symptom thereof in the subject.
[0123] When the level of the biomarker molecule is equal to the cutoff value, it is predicted that the bispecific fusion polypeptide will be effective or ineffective in treating SSc or a symptom thereof in the subject, and this can be set arbitrarily depending on the purpose of the prediction, etc. Thus, in one aspect, when the level of the biomarker molecule is equal to or greater than the cutoff value, it is predicted that the bispecific fusion polypeptide will be effective in treating SSc or a symptom thereof in the subject, and when the level of the biomarker molecule is below the cutoff value, it is predicted that the bispecific fusion polypeptide will not be effective in treating SSc or a symptom thereof in the subject. In another aspect, when the level of the biomarker molecule is higher than the cutoff value, it is predicted that the bispecific fusion polypeptide will be effective in treating SSc or a symptom thereof in the subject, and when the level of the biomarker molecule is equal to or less than the cutoff value, it is predicted that the bispecific fusion polypeptide will not be effective in treating SSc or a symptom thereof in the subject.
[0124] The cutoff value is a value that can statistically significantly separate a group of subjects for whom the bispecific fusion polypeptide is effective in treating SSc or its symptoms from a group of subjects for whom the bispecific fusion polypeptide is not effective. The cutoff value can be set by known methods using various statistical analysis techniques. For example, the cutoff value can be set by statistically analyzing the levels of biomarker molecules in samples obtained from a group of subjects for whom the bispecific fusion polypeptide is effective in treating SSc or its symptoms and the levels of biomarker molecules in samples obtained from a group of subjects for whom the bispecific fusion polypeptide is not effective. Statistical significance can be analyzed using known testing methods such as the chi-square test, generalized Wilcoxon test, Wilcoxon signed-rank test, Mann-Whitney test, log-rank test, and Cox proportional hazards. Statistical analysis software such as SAS 9.2 software can be used to set the cutoff value.
[0125] The cutoff value may be set based on sensitivity and / or specificity. Preferably, the cutoff value exhibits both high sensitivity and high specificity. Sensitivity refers to the true positive rate, and specificity refers to the true negative rate. For example, the cutoff value may be set to a level of a biomarker molecule that exhibits a high positive rate in a group in which treatment of SSc with a bispecific fusion polypeptide is effective and a high negative rate in a group in which treatment is not effective.
[0126] For example, a cutoff value can be set using receiver operating characteristic (ROC) analysis, a commonly used method for examining the usefulness of diagnostic tests. In ROC analysis, an ROC curve is created by plotting the sensitivity at each cutoff value on the vertical axis and the false positive rate (1 - specificity) on the horizontal axis. For tests without diagnostic ability, the ROC curve is a diagonal straight line, but as the diagnostic ability improves, the curve becomes more arched upward to the left. The cutoff value that gives the point on the ROC curve with the smallest distance from the upper left corner is said to have excellent sensitivity and specificity. The cutoff value can also be set based on the Youden index. Specifically, sensitivity and specificity are determined from the levels of biomarker molecules in groups in which treatment of SSc with a bispecific fusion polypeptide was effective and groups in which it was not effective, and an ROC curve is created based on these values using commercially available analysis software. The values at which sensitivity and specificity are as close to 100% as possible are then determined, and these values can be used as the cutoff value.
[0127] Alternatively, for example, the diagnostic efficiency (i.e., the ratio of the total number of cases in which subjects for whom treatment of SSc with the bispecific fusion polypeptide was correctly diagnosed as "effective" and the total number of cases in which subjects for whom treatment was not effective were correctly diagnosed as "ineffective") to the total number of cases may be calculated, and the level of the biomarker molecule that gives the highest diagnostic efficiency may be used as the cutoff value.
[0128] Alternatively, the cutoff value may be determined based on the levels of the biomarker molecules in a group of healthy animals of the same species as the subject, for example, the mean, 55th, 60th, 65th, 70th, 75th, 80th, 85th, 90th, or 95th percentile of the levels of the biomarker molecules measured in a group of healthy animals.
[0129] Cutoff values can also be set for patient subgroups according to characteristics, for example, cutoff values may be set according to gender, age group, or race.
[0130] In one embodiment, the biomarker molecule is at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, EFEMP1, and SPON1, e.g., at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, and EFEMP1, and if the level of said biomarker molecule is high compared to the cutoff value, it is predicted that the bispecific fusion polypeptide will be effective in treating pulmonary symptoms of systemic sclerosis in the subject.
[0131] In one aspect, the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CHI3L1, EFEMP1, PLAUR, and SPON1, e.g., at least one biomarker molecule selected from GDF15, LTBP2, CHI3L1, EFEMP1, and PLAUR, and when the level of said biomarker molecule is high compared to the cutoff value, it is predicted that the bispecific fusion polypeptide will be effective in treating pulmonary hypertension in systemic sclerosis in the subject.
[0132] In one embodiment, the method can be used to aid in the diagnosis or treatment of SSc. Alternatively, the prediction results of the method can be provided as information for the diagnosis or treatment of SSc. In one embodiment, the method can include collecting a sample from a subject. In one embodiment, the method can include measuring the level of a biomarker molecule. In one embodiment, the method can include administering a bispecific fusion polypeptide to a subject for whom the bispecific fusion polypeptide is predicted to be effective in treating systemic sclerosis or a symptom thereof.
[0133] In another aspect, a kit is provided for predicting the efficacy of a bispecific fusion polypeptide in a subject, comprising at least one reagent that specifically binds to at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1.
[0134] The kit may contain a single reagent that specifically binds to a biomarker molecule, or may contain any combination of multiple reagents. That is, the kit may contain a single reagent that binds to any one biomarker molecule selected from IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1, or may contain a combination of reagents that bind to two, three, four, five, six, seven, or all eight biomarker molecules. In one aspect, the kit contains a reagent that binds to a biomarker molecule selected from IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, and PLAUR. The kit may further contain a reagent that specifically binds to IL-17a.
[0135] The reagents may be dissolved in water or a suitable buffer, such as phosphate-buffered saline (PBS), or may be provided in a lyophilized state in a suitable container. Suitable containers include bottles, vials, syringes, test tubes, plates, membranes, and the like. The containers may be made of a variety of materials, such as glass or plastic. When the kit includes multiple reagents, multiple reagents may be contained in one component, or multiple components may each contain one or more reagents. The kit may further include other components or reagents necessary for detecting biomarker molecules. For example, the kit may further include a labeled secondary antibody, a chromogenic substrate, a blocking solution, a washing buffer, and the like. The kit may further include other materials desirable from a commercial and user standpoint, such as a package insert containing instructions for use.
[0136] In one aspect, at least one reagent that specifically binds to at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1 is provided for predicting the efficacy of a bispecific fusion polypeptide in a subject. In one aspect, there is provided the use of at least one reagent that specifically binds to at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1 for the manufacture of a kit for predicting the efficacy of a bispecific fusion polypeptide in a subject.
[0137] Treatment of SSc Subjects predicted by the above method to be effective in treating SSc or a symptom thereof with a bispecific fusion polypeptide are recommended to receive treatment for SSc or a symptom thereof with the bispecific fusion polypeptide. Accordingly, in one aspect, a method for treating SSc or a symptom thereof is provided, comprising administering an effective amount of a bispecific fusion polypeptide to a subject predicted by the above method to be effective in treating SSc or a symptom thereof. Also provided is a pharmaceutical composition comprising a bispecific fusion polypeptide for treating SSc or a symptom thereof, to be administered to a subject predicted by the above method to be effective in treating SSc or a symptom thereof.
[0138] Pharmaceutical compositions can include a bispecific fusion polypeptide of the present disclosure and a pharmaceutically or physiologically acceptable carrier, diluent, or excipient. As used herein, the terms "pharmaceutically acceptable" and "physiologically acceptable" when referring to a carrier, diluent, or excipient can be a solvent (aqueous or non-aqueous), surfactant, solution, emulsion, dispersion medium, coating, or isotonic and absorption enhancers or retardants that are compatible with the pharmaceutical administration method and the other ingredients in the composition. Pharmaceutical compositions of the present disclosure can be provided in the form of tablets (coated or uncoated), capsules (hard or soft), microbeads, emulsions, powders, granules, crystals, suspensions, syrups, or elixirs.
[0139] Pharmaceutical compositions can be formulated to be compatible with specific administration routes or uses. Pharmaceutical compositions for parenteral, intradermal, or subcutaneous administration may contain sterile diluents such as water, saline, fixed oils, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents. The compositions may further contain one or more preservatives to prevent the growth of microorganisms (e.g., antibacterial agents such as benzyl alcohol or methylparaben; antibacterial agents such as benzyl alcohol or methylparaben; chelating agents such as EDTA; buffers such as acetate buffer, citrate buffer, or phosphate buffer, and additives for adjusting tonicity such as sodium chloride or dextrose).
[0140] The pharmaceutical composition for injection may be in the form of a sterile injectable solution or a sterile aqueous solution (water-soluble) for dispersion, or a ready-to-use form, consisting of a dispersion medium and a sterile powder. For intravenous administration, examples of suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (商標) (BASF, Parsippany, NJ) and phosphate buffered saline (PBS). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and polyethylene glycol), or suitable mixtures thereof. Fluidity can be maintained, for example, by the use of a coating such as lecithin or by the use of a surfactant. Examples of antibacterial and antifungal agents include parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal. The addition of an agent that delays absorption, such as aluminum monostearate and gelatin, can prolong absorption of the injectable compositions. Polysorbate 20 or polysorbate 80 may be added to the composition, for example, up to 1%. Other non-limiting examples of additives include histidine HCl and α,α-trehalose dihydrate.
[0141] Additional pharmaceutical formulations and delivery systems are known to those of skill in the art and can be used with the bispecific fusion polypeptides of the present disclosure (see, e.g., Remington's Pharmaceutical Sciences (1990) 18th ed., Mack Publishing Co., Easton, PA; The Merck Index (1996) 12th ed., Merck Publishing Group, Whitehouse, NJ; Pharmaceutical Principles of Solid Dosage Forms, Technonic Publishing Co., Inc., Lancaster, Pa., (1993); and Poznansky, et al., Drug Delivery Systems, R.L. Juliano, ed., Oxford, NY (1980), pp. 253-315).
[0142] The bispecific fusion polypeptides of the present disclosure can be formulated and / or administered in combination with a second agent. The bispecific fusion polypeptides of the present disclosure can be administered before, simultaneously with, or after the administration of the second agent. The fusion polypeptides of the present disclosure can be formulated in combination with a second agent. Non-limiting examples of second agents include steroids, cyclophosphamide, proton pump inhibitors, prostacyclin, ACE inhibitors, and endothelin receptor antagonists.
[0143] An effective or sufficient amount of the bispecific fusion polypeptide is administered to a subject. By "effective amount" or "sufficient amount" is meant that amount, in single or multiple doses, alone or in combination with one or more other components (therapeutic agents such as drugs), treatments, protocols, or therapeutic regimens, that provides an expected or desired result or benefit to the subject, with a detectable response of any duration (long-term or short-term), to any measurable or detectable degree, or for any period of time (e.g., minutes, hours, days, months, years, or cure).
[0144] The term "effective amount" or "sufficient amount" for purposes of treatment (e.g., ameliorating or providing a therapeutic benefit or improvement) generally means an amount effective to measurably reduce, decrease, inhibit, suppress, limit or control one, more or all adverse symptomatic responses, disorders or diseases, consequences or complications of said responses, disorders or diseases, or the progression or worsening of adverse symptoms thereof, in a cell, tissue or organ, to produce a satisfactory result.
[0145] An effective or sufficient amount may, but need not, be provided in a single dose, but may require multiple doses, and may be administered alone or in combination with another composition (e.g., a drug), treatment, protocol, or therapeutic regimen. For example, the amount can be titrated upward as indicated by the subject's needs, the type, condition, and severity of the disorder or disease being treated, or the side effects of the treatment (if any). In addition, an effective or sufficient amount need not be effective or sufficient when provided in a single or multiple doses without a second composition (e.g., another drug or drug), treatment, protocol, or therapeutic regimen, as additional doses, amounts, or durations above and doses exceeding such doses, or additional compositions (e.g., multiple drugs or medications), treatments, protocols, or therapeutic regimens may be included to be considered effective or sufficient in a given subject. Amounts considered effective also include amounts that result in the reduction of the use of another treatment, therapeutic regimen, or protocol. The appropriate amount will vary depending on the condition being treated, the desired therapeutic effect, and the individual subject (e.g., the subject's bioavailability, gender, or age).
[0146] Compositions containing bispecific fusion polypeptides can be packaged in single dosage forms for ease of administration and uniformity of dosage. As used herein, "single dosage form" refers to physically discrete units suitable for single-dose treatment. Each unit contains an amount of composition calculated to produce a desired treatment or therapeutic (e.g., beneficial) effect, in association with a carrier, excipient, diluent, or vehicle. The single dosage form will vary depending on several factors, including, but not limited to, the particular composition used, the disorder or disease being treated, the effect to be achieved, and the subject to be treated. Exemplary unit doses are in the ranges of about 25-250, 250-500, 500-1,000, 1,000-2,500, 2,500-5,000, 5,000-25,000, or 5,000-50,000 pg; about 50-500, 500-5,000, 5,000-25,000, or 25,000-50,000 ng; about 50-500, 500-5,000, 5,000-25,000, or 25,000-50 ,000 μg; in the range of about 25-250, 250-500, 500-1,000, 1,000-2,500, 2,500-5,000, 5,000-25,000 or 5,000-50,000 mg; and in the range of about 1-5, 5-10, 10-25, 25-50, 50-100, 100-250, 250-500, 500-1,000, 1,000-2,500 or 2,500-5,000 grams.
[0147] As described herein, bispecific fusion polypeptides and compositions thereof can be administered or delivered in vivo to a subject or patient in various doses and amounts, and frequencies. For example, the fusion polypeptides or compositions thereof can be administered or delivered as single or multiple doses, e.g., in an effective or sufficient amount, to provide the intended effect. Exemplary doses range from about 25-250, 250-500, 500-1,000, 1,000-2,500, 2,500-5,000, 5,000-25,000, or 5,000-50,000 pg / kg daily, every other day, or intermittently. / kg; in the range of about 50-500, 500-5,000, 5,000-25,000 or 25,000-50,000 μg / kg; and in the range of about 25-250, 250-500, 500-1,000, 1,000-2,500, 2,500-5,000, 5,000-25,000 or 5,000-50,000 mg / kg.
[0148] Single or multiple (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) administrations or doses of the composition may be administered on the same or consecutive days, every other day, or intermittently. For example, a composition comprising a bispecific fusion polypeptide may be administered once, twice, three times, four or more times daily, every other day, every other week, weekly, monthly, bimonthly, or yearly. A composition comprising a bispecific fusion polypeptide may be administered for any suitable period of time, for example, within an hour or less, for example, within 30 minutes or less, 15 minutes or less, 5 minutes or less, or 1 minute or less.
[0149] A composition comprising a bispecific fusion polypeptide may be administered to a subject prior to, substantially simultaneously with, or within about 1 to 60 minutes, hours (e.g., 1, 2, 3, 4, 5, 6, 8, 12, 24 hours), or days (1, 2, 3, 4, 5, 6, 7, 7-14, 14-21, 21-28, 28-45, 45-60, or 60-90 days) of the onset of SSc or symptoms thereof.
[0150] Compositions comprising bispecific fusion polypeptides can be administered systemically or locally by any route. For example, compositions comprising fusion polypeptides can be administered systemically or locally by injection, infusion, orally (e.g., ingestion or inhalation), topically, intravenously, intraarterially, intramuscularly, intraperitoneally, intradermally, subcutaneously, intracavity, intracranially, transdermal (topical), parenterally, e.g., via a transmucosal or rectal (enema) catheter, or intraocularly. Administration may also be via (micro)encapsulated delivery systems or administration implant packages.
[0151] The present disclosure also provides kits comprising bispecific fusion polypeptides packaged in suitable packaging material. The kits may include a label or packaging insert containing descriptions of the components or instructions for use of the components contained therein. Examples of instructions include instructions for a method, treatment protocol, or therapeutic regimen.
[0152] The kit can contain a collection of components, for example, two or more compositions each containing a different bispecific fusion polypeptide, or a composition containing a bispecific fusion polypeptide and another therapeutically useful agent. The term "packaging material" refers to a physical structure that contains the components of the kit. The packaging material is capable of maintaining the components in a sterile condition and can be made of materials commonly used for such purposes (e.g., paper, cardboard, glass, plastic, foil, ampoules, vials, or tubes).
[0153] The kit may include a label or insert. The label or insert may be "printed," e.g., paper or cardboard, or may be separate or affixed to the component, kit, or packaging material (e.g., box), or may be attached to the ampoule, tube, or vial containing the kit component. The label or insert may be a computer readable medium, a CD- or DVD-ROM / RAM, a DVD, MP3, an optical disk such as magnetic tape, or an electronic storage medium such as RAM and ROM, or a hybrid thereof such as a magnetic / optical storage medium, FLASH media, or a memory-type card.
[0154] The label or insert may include information identifying one or more of the components therein, the dosage, mechanism of action, pharmacokinetics (PK), and pharmacodynamics (PD) of the active ingredient(s). The label or insert may include information identifying the manufacturer, lot number, location and date of manufacture.
[0155] The label or insert may include information regarding the condition, disorder, disease, or symptom for which the kit components can be used. The label or insert may include instructions for a physician or subject for using one or more of the kit components in a method, treatment protocol, or therapeutic regimen. The instructions may include dosage, frequency, or duration, and instructions for practicing any of the methods, treatment protocols, or therapeutic regimens described herein. Thus, the kits of the present disclosure may further include a label or instructions for practicing any of the methods and uses described herein.
[0156] The label or insert may include information regarding any benefit the component may provide, such as a prophylactic or therapeutic benefit. The label or insert may include information about possible adverse side effects, such as warnings to the subject or physician regarding situations in which it is not appropriate to use a particular composition. Because adverse side effects may also occur when the subject has been, may be taking, or is currently taking one or more other medications that may be incompatible with the composition, or when the subject has been, may be taking, or is currently undergoing another treatment protocol or therapeutic regimen that may be incompatible with the composition, the instructions may include information regarding such incompatibilities.
[0157] The kit may further include other components. Each component of the kit may be enclosed in an individual container, and all of the various containers may be in a single package. The kits of the present disclosure may be designed for refrigerated storage.
[0158] In one aspect, a bispecific fusion polypeptide is provided for use in treating SSc or a symptom thereof in a subject predicted by the above method for which the bispecific fusion polypeptide will be effective. In one aspect, a use of a bispecific fusion polypeptide in treating SSc or a symptom thereof in a subject predicted by the above method for which the bispecific fusion polypeptide will be effective is provided. In one aspect, a use of a bispecific fusion polypeptide for the manufacture of a composition for treating SSc or a symptom thereof in a subject predicted by the above method for which the bispecific fusion polypeptide will be effective is provided.
[0159] For example, the following embodiments are provided: [1] A method for predicting the efficacy of a bispecific fusion polypeptide in a subject, comprising comparing the level of a biomarker molecule in a sample collected from the subject with a cutoff value for the biomarker molecule, wherein the subject is suffering from systemic sclerosis, the biomarker molecule is at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1, and the bispecific fusion polypeptide comprises a phenomeric sequence that binds to IL-17a and forms a complex with an antibody that binds to IL-6R or a subsequence thereof having IL-6R binding ability. [2] The method of [1], comprising comparing the level of IL-6 with a cutoff value for IL-6. [3] The method of [1] or [2], comprising comparing the level of GDF15 with a cutoff value for GDF15. [4] The method of any of [1] to [3], comprising comparing the level of LTBP2 with a cutoff value for LTBP2. [5] The method of any of [1] to [4], comprising comparing the level of CCL7 with a cutoff value for CCL7. [6] The method of any of [1] to [5], comprising comparing the level of CHI3L1 with a cutoff value for CHI3L1. [7] The method of any of [1] to [6], comprising comparing the level of EFEMP1 with a cutoff value for EFEMP1. [8] The method of any of [1] to [7], comprising comparing the level of PLAUR with a cutoff value for PLAUR. [9] The method of any of [1] to [8], comprising comparing the level of SPON1 with a cutoff value for SPON1.
[10] The method according to [1], wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR and SPON1.
[0160]
[11] The method of [1], wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, and PLAUR.
[12] The method of
[10] or
[11] , further comprising comparing the level of IL-6 with an IL-6 cutoff value.
[13] The method of any of [1] to
[12] , wherein a bispecific fusion polypeptide is predicted to be effective in treating systemic sclerosis or a symptom thereof in a subject when the level of the biomarker molecule is high compared to the cutoff value of the biomarker molecule.
[14] The method of any of [1] to
[13] , wherein a bispecific fusion polypeptide is predicted to be ineffective in treating systemic sclerosis or a symptom thereof in a subject when the level of the biomarker molecule is low compared to the cutoff value of the biomarker molecule.
[15] The method of any of [1] to
[14] , further comprising measuring the level of the biomarker molecule in a sample collected from the subject.
[16] The method of any of [1] to
[15] , wherein the subject's blood IL-6 level is higher than a value based on blood IL-6 levels measured in a group of healthy animals of the same species as the subject, and / or the subject's blood IL-17a level is higher than a value based on blood IL-17a levels measured in a group of healthy animals of the same species as the subject.
[17] The method of any of [1] to
[16] , wherein the subject's blood IL-6 level is higher than a value based on blood IL-6 levels measured in a group of healthy animals of the same species as the subject.
[18] The method of any of [1] to
[17] , wherein the subject's blood IL-17a level is higher than a value based on blood IL-17a levels measured in a group of healthy animals of the same species as the subject.
[19] The method according to any of [1] to
[18] , wherein the subject's blood IL-6 level is higher than a value based on blood IL-6 levels measured in a group of healthy animals of the same species as the subject, and the subject's blood IL-17a level is higher than a value based on blood IL-17a levels measured in a group of healthy animals of the same species as the subject.
[20] The method according to any one of [1] to
[19] , further comprising: (1) comparing the level of IL-6 in a sample collected from the subject with a cutoff value for IL-6; and / or (2) comparing the level of IL-17a in a sample collected from the subject with a cutoff value for IL-17a.
[0161]
[21] The method of any of [1] to
[20] , wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, EFEMP1, and SPON1, and when the level of the biomarker molecule is higher compared to a cutoff value, it is predicted that the bispecific fusion polypeptide will be effective in treating a pulmonary symptom of systemic sclerosis in the subject.
[22] The method of
[21] , wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, and EFEMP1.
[23] The method of any of [1] to
[20] , wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CHI3L1, EFEMP1, PLAUR, and SPON1, and wherein the bispecific fusion polypeptide is predicted to be effective in treating pulmonary hypertension associated with systemic sclerosis in a subject when the level of the biomarker molecule is higher than a cutoff value.
[24] The method of
[23] , wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CHI3L1, EFEMP1, and PLAUR.
[25] The method of any of [1] to
[24] , wherein the systemic sclerosis is diffuse cutaneous scleroderma.
[26] The method of any of [1] to
[24] , wherein the systemic sclerosis is limited cutaneous scleroderma.
[27] The method of any of [1] to
[26] , wherein the sample is blood, plasma, or serum.
[28] The method of any one of [1] to
[27] , which comprises administering a bispecific fusion polypeptide to a subject predicted to be effective against the bispecific fusion polypeptide.
[29] A method for treating systemic sclerosis or a symptom thereof, which comprises administering an effective amount of a bispecific fusion polypeptide to a subject, wherein the subject is predicted to be effective against the bispecific fusion polypeptide by the method of any one of [1] to
[27] , and the bispecific fusion polypeptide comprises a phenomer sequence that binds to IL-17a and forms a complex with an antibody that binds to IL-6R or a partial sequence thereof that has IL-6R binding ability.
[30] A pharmaceutical composition for treating systemic sclerosis or symptoms thereof, which is administered to a subject for whom a bispecific fusion polypeptide is predicted to be effective by the method of any one of [1] to
[27] , and which comprises a bispecific fusion polypeptide that binds to IL-17a and contains a phenomer sequence that forms a complex with an antibody that binds to IL-6R or a partial sequence thereof that has IL-6R binding ability.
[0162]
[31] A kit for predicting the efficacy of a bispecific fusion polypeptide in a subject, comprising at least one reagent that specifically binds to at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1, wherein the subject is suffering from systemic sclerosis, and the bispecific fusion polypeptide comprises a phenomeric sequence that binds to IL-17a and forms a complex with an antibody that binds to IL-6R or a subsequence thereof that has IL-6R-binding ability.
[32] The kit of
[31] , comprising a reagent that specifically binds to IL-6.
[33] The kit of
[31] or
[32] , comprising a reagent that specifically binds to GDF15.
[34] The kit of any of
[31] to
[33] , comprising a reagent that specifically binds to LTBP2.
[35] The kit of any of
[31] to
[34] , comprising a reagent that specifically binds to CCL7.
[36] The kit according to any one of
[31] to
[35] , comprising a reagent that specifically binds to CHI3L1.
[37] The kit according to any one of
[31] to
[36] , comprising a reagent that specifically binds to EFEMP1.
[38] The kit according to any one of
[31] to
[37] , comprising a reagent that specifically binds to PLAUR.
[39] The kit according to any one of
[31] to
[38] , comprising a reagent that specifically binds to SPON1.
[40] The kit according to
[31] , comprising at least one reagent that specifically binds to at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR, and SPON1.
[0163]
[41] The kit according to
[31] , further comprising at least one reagent that specifically binds to at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, and PLAUR.
[42] The kit according to
[40] or
[41] , further comprising a reagent that specifically binds to IL-6.
[43] The kit according to any one of
[31] to
[42] , further comprising a reagent that specifically binds to IL-17a.
[44] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the bispecific fusion polypeptide comprises a fynomer sequence that binds to interleukin-17a (IL-17a) and interleukin-6 receptor (IL-6R) and forms a complex with an antibody or a subsequence thereof having IL-6R-binding ability, wherein the fynomer sequence maintains the motifs at positions 12 to 17 and the motifs at positions 31 to 36 of the amino acid sequence of any one of SEQ ID NOs: 1 to 7 and has at least 90% identity with said amino acid sequence, and wherein the bispecific fusion polypeptide binds to both IL-17a and IL-6R and inhibits the activities of both.
[45] The method, pharmaceutical composition, or kit according to
[44] , wherein the fynomer sequence comprises the QILSTHEYEDWWEAR motif at amino acid positions 28 to 42 of said sequence.
[46] The method, pharmaceutical composition, or kit according to
[44] or
[45] , wherein the fynomer sequence binds to glycosylated IL-17a and inhibits IL-17 receptor function or signal transduction.
[47] The method, pharmaceutical composition, or kit according to
[46] , wherein the fynomer sequence has a binding affinity (Kd) of 1 to 200 nM for glycosylated IL-17a.
[48] The method, pharmaceutical composition, or kit according to any one of
[44] to
[47] , wherein the fynomer sequence has a binding affinity (Kd or KD) for glycosylated IL-17a that is higher than the binding affinity for glycosylated IL-17a of the polypeptide of SEQ ID NO: 1.
[49] The method, pharmaceutical composition, or kit according to any one of
[44] to
[48] , wherein the fynomer sequence has at least 95% identity to a sequence set forth in any one of SEQ ID NOs: 1 to 7.
[50] The method, pharmaceutical composition, or kit according to
[49] , wherein the fynomer sequence has a sequence set forth in any one of SEQ ID NOs: 1 to 7.
[0164]
[51] The method, pharmaceutical composition, or kit according to any one of
[44] to
[50] , wherein the fynomer sequence forms a complex with the heavy or light chain sequence of an antibody that binds to IL-6R, or a partial sequence thereof that has IL-6R-binding ability.
[52] The method, pharmaceutical composition, or kit according to
[51] , wherein the fynomer sequence forms a complex with the amino or carboxyl terminus of the heavy chain sequence of an antibody that binds to IL-6R, or a partial sequence thereof that has IL-6R-binding ability.
[53] The method, pharmaceutical composition, or kit according to
[51] , wherein the fynomer sequence forms a complex with the amino or carboxyl terminus of the light chain sequence of an antibody that binds to IL-6R, or a partial sequence thereof that has IL-6R-binding ability.
[54] The method, pharmaceutical composition, or kit according to any one of
[44] to
[53] , wherein the fynomer sequence forms a complex via a linker with the heavy or light chain sequence of an antibody that binds to IL-6R, or a partial sequence thereof that has IL-6R-binding ability.
[55] The method, pharmaceutical composition, or kit according to any one of
[44] to
[54] , wherein the fusion polypeptide simultaneously binds to IL-17a and IL-6R.
[56] The method, pharmaceutical composition, or kit according to any one of
[44] to
[55] , wherein the fusion polypeptide simultaneously binds to IL-17a and IL-6R.
[57] The method, pharmaceutical composition, or kit according to any one of
[44] to
[56] , wherein the antibody that binds to IL-6R or a partial sequence thereof having IL-6R binding ability comprises a heavy chain (HC) having the following variable regions CDR1-3: SDHAWS; YSYSGITTYNPSLKS; and SLARTTAMDY, and a light chain (LC) having the following variable regions CDR1-3: RASQDISSYLN; YTSRLHS; and QQGNTLPYT.
[58] The method, pharmaceutical composition, or kit according to
[57] , wherein the antibody that binds to IL-6R comprises a HC having an amino acid sequence at least 90% identical to the sequence of SEQ ID NO: 12 and a LC having an amino acid sequence at least 90% identical to the sequence of SEQ ID NO: 13.
[59] The method, pharmaceutical composition, or kit according to
[58] , wherein the antibody that binds to IL-6R comprises the amino acid sequences set forth in SEQ ID NOs: 12 and 13.
[60] A heavy chain having an amino acid sequence that has at least 90% identity with SEQ ID NO: 14 and a light chain having an amino acid sequence that has at least 90% identity with SEQ ID NO: 15 in the following heavy chain (HC) and light chain (LC) sequences: (HC) SEQ ID NO: 14; (LC) SEQ ID NO: 15; (HC) SEQ ID NO: 16; (LC) SEQ ID NO: 17; (HC) SEQ ID NO: 18; (LC) SEQ ID NO: 19; (HC) SEQ ID NO: 20; (LC) SEQ ID NO: 21; (HC) SEQ ID NO: 22; (LC) SEQ ID NO: 23; (HC) SEQ ID NO: 24; (LC) SEQ ID NO: 25; (HC) SEQ ID NO: 26; (LC) SEQ ID NO: 27; (HC) SEQ ID NO: 28; (LC) SEQ ID NO: 29, The method, pharmaceutical composition, or kit according to
[57] , comprising any combination of: a heavy chain having an amino acid sequence at least 90% identical to SEQ ID NO: 18 and a light chain having an amino acid sequence at least 90% identical to SEQ ID NO: 19; a heavy chain having an amino acid sequence at least 90% identical to SEQ ID NO: 20 and a light chain having an amino acid sequence at least 90% identical to SEQ ID NO: 21; a heavy chain having an amino acid sequence at least 90% identical to SEQ ID NO: 22 and a light chain having an amino acid sequence at least 90% identical to SEQ ID NO: 23; a heavy chain having an amino acid sequence at least 90% identical to SEQ ID NO: 24 and a light chain having an amino acid sequence at least 90% identical to SEQ ID NO: 25; a heavy chain having an amino acid sequence at least 90% identical to SEQ ID NO: 26 and a light chain having an amino acid sequence at least 90% identical to SEQ ID NO: 27; a heavy chain having an amino acid sequence at least 90% identical to SEQ ID NO: 28 and a light chain having an amino acid sequence at least 90% identical to SEQ ID NO: 29.
[0165]
[61] The method, pharmaceutical composition, or kit according to
[60] , wherein the antibody that binds to IL-6R comprises HC and LC amino acid sequences selected from any combination of SEQ ID NOs: 14 and 15, 16 and 17, 18 and 19, 20 and 21, 22 and 23, 24 and 25, 26 and 27, and 28 and 29.
[62] The method, pharmaceutical composition, or kit according to any of
[44] to
[61] , wherein the fusion polypeptide binds to human IL-17a or IL-6R.
[63] The method, pharmaceutical composition, or kit according to any of [1] to
[43] , wherein a finomer sequence forms a complex with the heavy or light chain sequence of the antibody, or a subsequence thereof.
[64] The method, pharmaceutical composition, or kit according to any of [1] to
[43] , wherein a finomer sequence forms a complex with the amino terminus or carboxyl terminus of the heavy chain sequence of the antibody, or a subsequence thereof.
[65] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the finomer sequence forms a complex with the amino or carboxyl terminus of the light chain sequence of the antibody or a subsequence thereof.
[66] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] and
[63] to
[65] , further comprising one or more additional IL-17a-binding finomer sequences that form a complex with the antibody or a subsequence thereof.
[67] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] and
[63] to
[66] , further comprising 3, 4, 5, 6, 7, or 8 IL-17a-binding finomer sequences that form a complex with the antibody or a subsequence thereof.
[68] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the finomer sequence is about 10 to 80 amino acids in length.
[69] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the finomer sequence is about 10 to 80 amino acids in length for IL-17a. -9 About 10 minutes from M -13 The binding affinity of M (K d
[70] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the finomer sequence comprises a sequence having at least 90% identity with any one of SEQ ID NOs: 1 to 7.
[0166]
[71] The method, pharmaceutical composition or kit according to any one of [1] to
[43] , wherein the fynomer sequence comprises a sequence having at least 95% identity to any one of SEQ ID NOs: 1 to 7.
[72] The method, pharmaceutical composition or kit according to any one of [1] to
[43] , wherein the fynomer sequence comprises any of the following sequences: SEQ ID NOs: 1 to 7, or any of the above fynomer sequences having 1-2, 2-3, 3-4, 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-25 or 25-30 conservative, non-conservative, or conservative and non-conservative amino acid substitutions.
[73] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fenomeric sequence comprises any of the following sequences: SEQ ID NOs: 1 to 7, or any of the above fenomeric sequences having 1-2, 2-3, 3-4, 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-25, or 25-30 amino acid deletions or insertions.
[74] The method, pharmaceutical composition, or kit according to
[72] or
[73] , wherein the fenomeric sequence has one or more of the motifs GVTLFVALYDY, DLSFHKGEKFQIL, STHEYE, STHEYED, WWEAR, DWWEAR, and SLTTGETGYIPSNYVAPVDSIQ.
[75] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fynomer sequence comprises a STHEYE motif at amino acid positions 31-36 of the sequence, or a QILSTTHEYEDWWEAR motif at amino acid positions 28-42 of the sequence.
[76] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fynomer sequence has an E residue positioned immediately after the src loop sequence.
[77] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fynomer sequence has an E residue positioned immediately after the src loop sequence, STHEY.
[78] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fynomer sequence binds to IL-17a and inhibits IL-17 response or signaling function.
[79] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fynomer sequence binds to glycosylated IL-17a and inhibits IL-17 receptor function or signaling.
[80] The phenomeric sequence exhibits a binding affinity (K ) of about 1 to about 200 nM for glycosylated IL-17a. d The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein
[0167]
[81] The phenomeric sequence has a binding affinity (K) of about 5 to about 50 nM for glycosylated human IL-17a. d
[82] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the phenomeric sequence has a higher binding affinity (K) for glycosylated IL-17a than the phenomeric sequence set forth in SEQ ID NO: 1. d
[83] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fynomer sequence binds to glycosylated IL-17a and inhibits IL-6 production by fibroblasts.
[84] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fynomer sequence has an IC50 of about 10 to about 250 nM, or about 10 to about 100 nM for inhibiting IL-6 production by fibroblasts. 50
[85] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fusion polypeptide simultaneously binds to IL-17a and IL-6R.
[86] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the antibody or a subsequence thereof is a human antibody or a humanized antibody or a subsequence thereof.
[87] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the subsequence of the antibody that binds to IL-6R is about 50 to 100 amino acids in length.
[88] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the antibody or a subsequence thereof binds to IL-6R with a length of about 10 -5 About 10 minutes from M -13 The binding affinity of M (K d
[89] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the antibody or a partial sequence thereof is Fab, Fab', F(ab') 2 , Fv, Fd, single-chain Fv (scFv), disulfide-linked Fv (sdFv), V L , VH , diabody ((V L -V H ) 2 Or (V H -V L ) 2 ), triabody (trivalent antibody), tetrabody (tetravalent antibody), minibody ((scF V -C H 3) 2 ), IgGdeltaCH2, scFv-Fc or (scFv) 2
[90] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the antibody is of the IgG, IgA, IgE, IgM, or IgD isotype.
[0168]
[91] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the antibody or a subsequence thereof comprises a sequence having at least 90% identity with the variable sequence of either the heavy chain (HC) sequence of SEQ ID NO: 12 or the light chain (LC) sequence of SEQ ID NO: 13.
[92] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the antibody or a subsequence thereof comprises a sequence having at least 95% identity with the variable sequence of either the heavy chain (HC) sequence of SEQ ID NO: 12 or the light chain (LC) sequence of SEQ ID NO: 13.
[93] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the antibody or a subsequence thereof comprises the variable sequence of either the heavy chain (HC) sequence of SEQ ID NO: 12 or the light chain (LC) sequence of SEQ ID NO: 13.
[94] The method, pharmaceutical composition, or kit according to any of [1] to
[43] , wherein the antibody or a subsequence thereof comprises a variable sequence of either the heavy chain (HC) sequence of SEQ ID NO: 12 or the light chain (LC) sequence of SEQ ID NO: 13, or a sequence having 1-2, 2-3, 3-4, 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-25, or 25-30 conservative, non-conservative, or conservative and non-conservative amino acid substitutions, or amino acid insertions or deletions, within or outside the variable sequence of either the above heavy chain (HC) or light chain (LC) sequences.
[95] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the antibody or a subsequence thereof comprises or consists of the following heavy chain (HC) and / or light chain (LC) sequences: (HC) SEQ ID NO: 14; (LC) SEQ ID NO: 15 (aka COVA 801); (HC) SEQ ID NO: 16; (LC) SEQ ID NO: 17 (aka COVA 802); (HC) SEQ ID NO: 18; (LC) SEQ ID NO: 19 (aka COVA 803); (HC) SEQ ID NO: 20; (LC) SEQ ID NO: 21 (aka COVA 804); (HC) SEQ ID NO: 22; (LC) SEQ ID NO: 23 (aka COVA 805); (HC) SEQ ID NO: 24; (LC) SEQ ID NO: 25 (aka COVA 806); (HC) SEQ ID NO: 26; (LC) SEQ ID NO: 27 (aka COVA 807); (HC) SEQ ID NO:28; (LC) SEQ ID NO:29 (aka COVA 808), or a sequence having 1-2, 2-3, 3-4, 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-25, 25-30 conservative, non-conservative, or conservative and non-conservative amino acid substitutions, or amino acid insertions or deletions, within or outside the variable sequence of any of the above heavy chain (HC) or light chain (LC) sequences.
[96] The method, pharmaceutical composition, or kit according to
[94] or
[95] , wherein the amino acid substitutions, insertions, or deletions are within or outside the heavy chain or light chain variable region sequence.
[97] The method, pharmaceutical composition, or kit according to
[94] or
[95] , wherein the amino acid substitutions, insertions, or deletions are within or outside the complementarity-determining regions (CDRs) of the heavy chain or light chain variable region sequence.
[98] The method, pharmaceutical composition, or kit according to
[94] or
[95] , wherein the amino acid substitution, insertion, or deletion is within or outside the framework region (FR) of the heavy chain or light chain variable region sequence.
[99] The method, pharmaceutical composition, or kit according to any of [1] to
[43] , wherein the antibody or a subsequence thereof inhibits IL-6R function or signal transduction.
[100] The method, pharmaceutical composition, or kit according to any of [1] to
[43] , wherein the fusion polypeptide binds to mammalian IL-17a or IL-6R.
[0169]
[101] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the fusion polypeptide binds to human IL-17a or IL-6R.
[102] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the IL-17a to which the fusion polypeptide binds comprises or consists of the sequence of SEQ ID NO: 10.
[103] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the IL-6R to which the fusion polypeptide binds comprises or consists of the sequence of SEQ ID NO: 11.
[104] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the phenomer sequence forms a complex with an antibody heavy or light chain sequence, or a subsequence thereof, via a covalent bond.
[105] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the phenomer sequence forms a complex with an antibody heavy or light chain sequence, or a subsequence thereof, via an amide bond.
[106] The method, pharmaceutical composition, or kit according to any one of [1] to
[43] , wherein the phenomer sequence forms a complex with an antibody heavy chain or light chain sequence, or a subsequence thereof, via a linker.
[107] The method, pharmaceutical composition, or kit according to
[106] , wherein the linker is a peptide comprising about 1-5, 5-10, 10-15, 15-20, 20-25, 25-50, or 50-100 amino acid residues.
[108] The linker peptide is (GGGGGS) X (wherein X is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.)
[109] The method, pharmaceutical composition, or kit according to
[108] , wherein the linker peptide comprises or consists of GGGGSGGGGGSGGGGS.
[110] The method, pharmaceutical composition, or kit according to
[106] , wherein the linker comprises a carbon chain containing about 1-5, 5-10, 10-15, 15-20, 20-25, 25-50, or 50-100 carbon atoms.
[0170] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.
[0171] All patent applications, publications, patents, and other references, GenBank citations, and ATCC citations mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
[0172] As used herein, the singular includes the plural unless the context clearly dictates otherwise. Thus, for example, reference to a "biomarker molecule" or a "reagent" can include one or more such biomarker molecules, reagents, etc.
[0173] As used herein, numerical values are often presented in a range format throughout the specification. The use of the range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention unless otherwise expressly stated. Thus, a range includes all possible subranges, all individual numerical values within that range, and all integers within such ranges and fractions of numerical values or integers within a range, unless otherwise expressly stated. This interpretation applies in all contexts herein, regardless of the breadth of the range. Thus, for example, a description of a range of 90-100% includes 91-99%, 92-98%, 93-95%, 91-98%, 91-97%, 91-96%, 91-95%, 91-94%, 91-93%, etc. References to a range of 90-100% also include 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc.
[0174] Furthermore, a reference to a range of 1-5,000 times includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 times, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5 times, etc., 2.1, 2.2, 2.3, 2.4, 2.5 times, etc., as well as any numerical range within such ranges, for example, 1-2, 5-10, 10-50, 50-100, 100-500, 100-1000, 500-1000, 1000-2000, 1000-5000, etc. In a further example, KD 10 -5 M to about KD 10 -13 References to a range of M include any value or range within or including that value.
[0175] Also, as used herein, a series of ranges are disclosed throughout the specification. The use of a series of ranges includes the combination of upper and lower range limits to provide another range. This interpretation applies in all contexts herein, regardless of the broadness of the range. Thus, for example, recitation of a series of ranges, such as 5-10, 10-20, 20-30, 30-40, 40-50, 50-75, 75-100, 100-150, 150-200, includes ranges such as 5-20, 5-30, 5-40, 5-50, 5-75, 5-100, 5-150, 5-200, and 10-30, 10-40, 10-50, 10-75, 10-100, 10-150, 10-171, and 20-40, 20-50, 20-75, 20-100, 20-150, 20-200, etc.
[0176] The present invention is generally disclosed herein using affirmative language to describe numerous embodiments. The present invention also specifically includes embodiments that, in whole or in part, exclude certain subject matter, such as substances or materials, method steps and conditions, protocols, procedures, assays or analyses, etc. Thus, the present invention generally includes embodiments disclosed herein, even if the present invention is not expressly limited to such embodiments.
[0177] Numerous aspects of the invention have been described. Nevertheless, it will be understood that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, the following examples are intended to be illustrative, but not limiting, of the scope of the invention as set forth in the claims.
[0178] Step 1: Classification of Patients by Blood Levels of IL-6 and IL-17A. Analysis was performed using clinical information and serum samples from patients with systemic sclerosis (SSc). First, proteins in serum samples from 17 patients with diffuse cutaneous SSc (dcSSc), 58 patients with limited cutaneous SSc (lcSSc), and 38 healthy individuals were analyzed. The background and clinical data of the SSc patients are shown in Table 1. Continuous variables were summarized as mean ± standard deviation, and categorical variables were expressed as counts (proportions). To compare the two groups of dcSSc and lcSSc, the Welch Two-Sample t-test was used for continuous variables, and the Fisher exact test was used for categorical variables. The modified Rodnan total skinfold thickness score (mRSS) was significantly higher in the dcSSc group than in the lcSSc group, indicating that dcSSc patients had more severe skin symptoms than lcSSc patients. The incidence of interstitial pneumonia was significantly higher in the dcSSc group. The % vital capacity (%VC), % forced vital capacity (%FVC), and % diffusing capacity for carbon monoxide (%DLCO) were significantly lower in the dcSSc group than in the lcSSc group, reflecting the more severe pulmonary symptoms in dcSSc patients. Although there was a significant difference in forced expiratory volume in 1 second (FEV 1.0) between dcSSc and lcSSc patients, neither group demonstrated obstructive ventilatory impairment, as seen in chronic obstructive pulmonary disease. There was no significant difference in the prevalence of pulmonary arterial hypertension (PAH) between the two groups. The frequency of patients with detectable anticentromere antibodies was higher in the lcSSc group, and the frequency of patients with detectable antitopoisomerase antibodies was higher in the dcSSc group.
[0179]
[0180] A Proximity Extension Assay (PEA) provided by Olink Proteomics AB was used to measure 1,472 proteins in serum. Measurement results were expressed as normalized protein eXpression (NPX). NPX is a relative protein quantification unit developed by Olink and is known to produce data that follow a normal distribution. Statistical analysis of serum protein concentrations was performed using NPX, assuming normal distribution of the data. To identify differentially expressed proteins (DEPs) between two healthy control groups, a linear model was applied using R version 4.2.0 and the Limma package (version 3.52.1). Proteins with a two-fold or greater variation and a corrected P value of 0.05 or less were considered to be DEPs with significant variation.
[0181] The blood levels of IL-6 and IL-17A in SSc patients were compared with those in healthy controls. The results are shown in Figure 2 using boxplots and dot plots. A significant increase in IL-6 was observed in SSc patients compared with healthy controls. No statistically significant differences were observed in the changes in IL-17A. Some SSc patient samples were found to be outside the distribution of each cytokine seen in healthy controls. The 95th percentile of healthy controls was used as the threshold, and samples exceeding the threshold were classified as high-level samples. SSc patient samples were classified into four clusters according to their blood levels of IL-6 and IL-17A. The names and definitions of each cluster are as follows: the first is the "Negative" cluster, consisting of samples with both IL-6 and IL-17A levels below the threshold. This cluster accounts for approximately 46% of SSc patients. The second is the "IL6" cluster, in which only IL-6 exceeds the threshold. This cluster accounts for approximately 24% of SSc patient samples. The third cluster is the "IL17" cluster, in which only IL-17A exceeds the threshold. This cluster accounts for approximately 7% of SSc patient samples. The fourth cluster is the "IL6_IL17" cluster, which consists of samples in which both IL-6 and IL-17A exceed the threshold. This cluster accounts for approximately 24% of SSc patient samples.
[0182] Step 2: Analysis of clinical characteristics of the high IL-6 and IL-17A group We searched for clinical symptoms characteristic of the high IL-6 and IL-17A group (the "IL6_IL17" cluster). The results are shown in Figure 3. Comparisons between clusters were performed using a paired comparison of the "Negative" cluster. For comparisons between clusters, Welch's two-sample t-test was used for continuous variables, and Fisher's exact test was used for categorical variables. # P value < 0.05: significant difference between each cluster and the "Negative" cluster (Welch's two-sample t-test). + P value < 0.05: significant difference between each cluster and the "Negative" cluster (Fisher's exact test). The "IL6_IL17" cluster had a lower %DLCO and a higher prevalence of PAH compared to the "Negative" cluster. The %DLCO of the "IL6_IL17" cluster was 46.2 ± 22.5, and the "IL6_IL17" cluster is considered to exhibit severe pulmonary dysfunction (normal range: 80-120%). The "IL6_IL17" cluster is characterized by severe pulmonary dysfunction and a high incidence of pulmonary hypertension.
[0183] Step 3: Identifying proteins correlated with %DLCO or PAH. Proteins correlated with %DLCO or PAH were searched for. The distribution of the difference in protein abundance (Log2 Fold change) between each cluster and the healthy control group is shown as a volcano plot in Figure 4. The volcano plot shows the difference in protein abundance (Log2 Fold change) on the X-axis and the -Log10 transformed P value on the Y-axis for each protein. To identify differentially expressed DEPs in the comparison between each cluster and the healthy control group, a linear model was applied using the R Limma package. Proteins with a two-fold or greater change and a corrected P value of 0.05 or less were considered significantly different DEPs. Proteins with significant differences were color-coded. The total number of DEPs was 141 (duplicates were present). The cluster with the highest number of DEPs was the "IL6_IL17" cluster, followed by the "IL6" cluster.
[0184] Next, we searched for DEPs correlated with %DLCO and the presence or absence of PAH. Bivariate correlation analysis was performed between each DEP and %DLCO or the presence or absence of PAH. In the correlation analysis between DEPs and %DLCO (continuous values), correlated DEPs were identified using a threshold of "Pearson's product-moment correlation coefficient of 0.4 or greater and a P value of 0.05 or less." As a result, 31 molecules (32 DEPs, including overlap with IL-6) were identified, and a list of these is shown in Table 2. In the correlation analysis between DEPs and the presence or absence of PAH (binary variables), correlated DEPs were identified using a threshold of "point biserial correlation coefficient of 0.4 or greater and a P value of 0.05 or less." As a result, 34 molecules were identified, and a list of these is shown in Table 3. Proteins common to Tables 2 and 3 are shown in bold.
[0185] To obtain additional information on cells expressing the identified molecules, lung single-cell RNA sequencing data from SSc patients was analyzed. The data used was GSE128169 (Ann Rheum Dis 2019; 78(10):1379-1387. PMID: 31405848) registered in the NCBI Gene Expression Omnibus. Publicly available processed data (raw counts in sparse matrix format) were analyzed using the Seurat package (version 4.1.1). The analysis method followed the method developed by Satija Lab (New York Genome Center), the developer of the Seurat package. To obtain cell annotation information, the Azimuth web app (https: / / azimuth.hubmapconsortium.org / ) developed by Satijya Lab was used, and cell annotation information from "Human Lung v2 (HLCA)" was applied. The expression of specific molecules was confirmed for each annotated cell, and the expression information in lung cells was summarized in Tables 2 and 3. Cells whose expression was confirmed by lung single-cell analysis are indicated by a "○".
[0186] SSc patients were classified by hierarchical clustering using 32 DEPs correlated with %DLCO. The results are shown as a heatmap in Figure 5. The rows of the heatmap show the 32 DEPs correlated with %DLCO, and the columns show SSc patients. Data were normalized (mean 0, variance 1) for each DEP, and hierarchical clustering was performed using Euclidean distance and Ward's method. Hierarchical clustering separated SSc patients into two clusters. One cluster consisted of patients with increased production of 32 proteins. Hereinafter, this cluster will be referred to as DLCO cluster 1, and the other cluster will be referred to as DLCO cluster 2. Patients with high IL-6 / IL-17A levels (15 / 16 cases) were classified into cluster 1. The %DLCO in DLCO cluster 1 was 39.9 ± 16.4 (mean ± standard deviation), which is considered "moderate to severe" according to the diagnostic criteria. On the other hand, the %DLCO in DLCO cluster 2 was 57.2±14.8, indicating a "moderate" severity. The %DLCO in "DLCO cluster 1" was significantly lower than that in DLCO cluster 2 (Figure 6; box-and-whisker plot). These results suggest that serum parameters (32 DEPs correlated with %DLCO) may be useful for distinguishing severely ill patients with impaired pulmonary function.
[0187] SSc patients were classified by hierarchical clustering using 34 DEPs correlated with the presence or absence of PAH. The results are shown as a heat map in Figure 7. The rows of the heat map show the 34 DEPs correlated with the presence or absence of PAH, and the columns show SSc patients. Data were standardized (mean 0, variance 1) for each DEP, and hierarchical clustering was performed using Euclidean distance and Ward's method. Hierarchical clustering separated SSc patients into three clusters, designated PAH cluster 1, PAH cluster 2, and PAH cluster 3. PAH cluster 1 and PAH cluster 2 consisted of patients with low to moderate concentrations of the 34 proteins. PAH cluster 3 consisted of patients with increased production of the 34 proteins (SD ≥ 2 after standardization). The majority of patients in PAH cluster 3 (8 of 9 cases) also had pulmonary hypertension. The proportion of patients with pulmonary hypertension in each cluster is shown (Figure 8a; 100% stacked graph). A definitive diagnosis of pulmonary hypertension (PAH) is a mean pulmonary arterial pressure (mPAP) of 25 mmHg or higher and a pulmonary artery wedge pressure (PCWP) of 15 mmHg or lower. Borderline PAH, defined as an mPAP of 21-24 mmHg, is known to be a risk group for PAH. A %FVC / %DLCO ratio of 1.6 or higher, based on an index obtained from pulmonary function tests, is a risk factor for pulmonary hypertension. The majority of patients in PAH clusters 3 and 1 had a %FVC / %DLCO ratio of 1.6 or higher, placing them at risk for PAH (Figure 8b). It was shown that serum parameters (34DEPs correlated with the presence or absence of PAH) can be used not only to distinguish between those with and without pulmonary hypertension, but also to select risk groups.
[0188]
[0189]
[0190]
[0191]
[0192]
[0193] Step 4: Identification of Biomarker Molecules MT-6194 is COVA806, described in International Publication No. 2015 / 141862 (Patent Document 1). It is a fusion polypeptide in which the phenomer of SEQ ID NO: 5 is attached to the C-terminus of the light chain of the anti-IL-6R antibody tricizumab via a 15-amino acid linker (GGGGS x 3), and it binds bispecifically to IL-6R and IL-17A. To identify the molecules affected by MT-6194, the effect of MT-6194 on human skin-derived fibroblasts was examined by transcriptome analysis. Normal human dermal fibroblasts (PromoCell: Cat. No. C-12302) were stimulated with serum from an SSc patient supplemented with cytokines (IL-6 (Peprotech: 200-06), IL-6R alpha (R&D systems: 227-SR), and IL-17A (Peprotech: 200-17)). The effects of MT-6194, an anti-IL-6R antibody (R&D systems: MAB227), and an anti-IL-17A antibody (Secukinumab) on gene expression changes in fibroblasts stimulated by this stimulation were evaluated. Transcriptome analysis was performed using a microarray (Clariom S Assay, human: Applied Biosystems). The total number of genes (DEGs) whose expression levels were upregulated by serum and cytokine stimulation from SSc patients was 2530. Of these, 1295 genes were affected by MT-6194 (Table 4). Representative results are shown in Figures 9 to 16.
[0194]
[0195] From the results of the serum sample analysis and transcriptome analysis, eight molecules were extracted and are shown in Table 5. That is, these eight molecules are molecules whose blood protein concentrations are high in the IL-6 and IL-17A high group ("IL6_IL17" cluster), correlate with clinical symptoms (%DLCO or the presence or absence of PAH), and whose gene expression is upregulated in skin fibroblasts stimulated with serum from SSc patients to which cytokines have been added, and whose expression is suppressed by MT-6194. Expression of all molecules was confirmed in the lung tissue of SSc patients.
[0196]
[0197] Furthermore, the patient classification performance of eight molecules was examined. The analysis results are shown in Figure 17 (classification of pulmonary hypertension) and Figure 18 (classification of decreased pulmonary function). In Figure 17, the classification performance of PAH clusters was examined using six molecules (GDF15, LTBP2, CHI3L1, EFEMP1, PLAUR, and SPON1) that correlate with the presence or absence of PAH. Principal component analysis using the six molecules (Figures 17a and 17b) demonstrated that the six molecules contribute to patient classification. ROC analysis for each molecule showed that each molecule had high performance in classifying PAH cluster 3 (AUC: >0.9) and low performance in classifying PAH cluster 1 (AUC: 0.498-0.745) (Figure 17c). To classify PAH cluster 1, a PAH risk group, a classification model was constructed using the six molecules using random forest (RF), a machine learning algorithm. The caret package (version 6.0-93) was used to construct the classification model. The cohort with recorded PAH was randomly divided into a training set and a test set at a 2:1 ratio. To determine the optimal λ value, 10-fold cross-validation was performed using the "λ.min" criterion, where λ represents the model with the most regularized λ value with the minimum mean square error between the estimated and observed values. One thousand independent classification models were created with varying random number seeds. To assess the classification performance of random forest (RF), the AUC of the ROC curve for each classification model was used as the model metric. The AUC of RF was compared with the AUC of each molecule (Figure 17d). The classification model using random forest (RF) demonstrated high performance. The importance of the six molecules at this time is shown in Figure 17e. These results suggest that classification models using multiple molecules contribute to patient classification, including PAH risk groups.
[0198] In the study shown in Figure 18, a similar study was performed on DLCO clusters. Regarding the classification of DLCO clusters, six molecules (IL-6, GDF15, LTBP2, CCL7, EFEMP1, and SPON1) correlated with %DLCO were shown to have cluster classification performance. Furthermore, a machine learning classification model using multiple molecules had even higher classification performance.
[0199] Therefore, these eight molecules may function as biomarkers for selecting patients suitable for treatment with MT-6164 in scleroderma. In addition, these eight molecules may also be used as markers for predicting the efficacy of treatment with MT-6164.
[0200] According to the present disclosure, the efficacy of a bispecific fusion polypeptide in a subject can be predicted, which is useful in the medical field.
Claims
1. A method for predicting the efficacy of a bispecific fusion polypeptide in a subject, comprising comparing the level of a biomarker molecule in a sample taken from the subject with a cutoff value for said biomarker molecule, wherein the subject suffers from systemic sclerosis, and the biomarker molecule is at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR and SPON1, and the bispecific fusion polypeptide comprises a fynomer sequence that binds to interleukin-17a (IL-17a) and forms a complex with an antibody that binds to interleukin-6 receptor (IL-6R) or a subsequence thereof having IL-6R binding ability, and the fynomer sequence maintains the motifs at positions 12 to 17 and the motifs at positions 31 to 36 of the amino acid sequence of any one of SEQ ID NOs: 1 to 7 and has at least 90% identity with said amino acid sequence, The bispecific fusion polypeptide binds to and inhibits the activity of both IL-17a and IL-6R.
2. The method of claim 1, wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR and SPON1.
3. The method of claim 2, further comprising comparing the level of IL-6 with a cutoff value for IL-6.
4. The method of any one of claims 1 to 3, wherein the bispecific fusion polypeptide is predicted to be effective in treating systemic sclerosis or a symptom thereof in a subject when the level of the biomarker molecule is high compared to a cutoff value of the biomarker molecule.
5. The method of any one of claims 1 to 4, further comprising measuring the level of said biomarker molecule in a sample taken from the subject.
6. The method of any one of claims 1 to 5, wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, EFEMP1 and SPON1, and when the level of the biomarker molecule is high compared to a cutoff value, it is predicted that the bispecific fusion polypeptide will be effective in treating a pulmonary symptom of systemic sclerosis in the subject.
7. The method of any one of claims 1 to 5, wherein the biomarker molecule is at least one biomarker molecule selected from the group consisting of GDF15, LTBP2, CHI3L1, EFEMP1, PLAUR and SPON1, and when the level of the biomarker molecule is high compared to a cutoff value, it is predicted that the bispecific fusion polypeptide will be effective in treating pulmonary hypertension of systemic sclerosis in the subject.
8. The method according to any one of claims 1 to 7, wherein the systemic sclerosis is diffuse cutaneous systemic sclerosis.
9. The method according to any one of claims 1 to 7, wherein the systemic sclerosis is limited cutaneous systemic sclerosis.
10. The method according to any one of claims 1 to 9, wherein the sample is blood, plasma or serum.
11. The method according to any one of claims 1 to 10, wherein the finomer sequence maintains the motifs at positions 12 to 17 and 31 to 36 of SEQ ID NO:
5.
12. The method according to any one of claims 1 to 11, wherein the antibody that binds to IL-6R or a partial sequence thereof having IL-6R binding ability comprises a heavy chain (HC) having the following variable regions CDR1-3: SDHAWS; YISYSGITTYNPSLKS; and SLARTTAMDY, and a light chain (LC) having the following variable regions CDR1-3: RASQDISSYLN; YTSRLHS; and QQGNTLPYT.
13. The method of claim 12, wherein the antibody that binds to IL-6R comprises a HC having an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO:12 and a LC having an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO:
13.
14. The method of claim 12, wherein the antibody that binds to IL-6R comprises a HC and a LC that are any combination of SEQ ID NOs:14 and 15, SEQ ID NOs:16 and 17, SEQ ID NOs:18 and 19, SEQ ID NOs:20 and 21, SEQ ID NOs:22 and 23, SEQ ID NOs:24 and 25, SEQ ID NOs:26 and 27, and SEQ ID NOs:28 and 29.
15. A method according to any one of claims 1 to 14, comprising administering a bispecific fusion polypeptide to a subject for whom the bispecific fusion polypeptide is predicted to be effective.
16. A pharmaceutical composition for treating systemic sclerosis or a symptom thereof, which is administered to a subject for whom a bispecific fusion polypeptide is predicted to be effective by the method of any one of claims 1 to 14, comprising a bispecific fusion polypeptide comprising a fynomer sequence that binds to interleukin-17a (IL-17a) and an antibody that binds to interleukin-6 receptor (IL-6R) or a partial sequence thereof having IL-6R binding ability, wherein the fynomer sequence maintains the motifs at positions 12 to 17 and the motifs at positions 31 to 36 of the amino acid sequence of any one of SEQ ID NOs: 1 to 7 and has at least 90% identity with said amino acid sequence, and the bispecific fusion polypeptide binds to both IL-17a and IL-6R and inhibits the activity of both.
17. A kit for predicting the efficacy of a bispecific fusion polypeptide in a subject, comprising at least one reagent that specifically binds to at least one biomarker molecule selected from the group consisting of IL-6, GDF15, LTBP2, CCL7, CHI3L1, EFEMP1, PLAUR and SPON1, wherein the subject suffers from systemic sclerosis, the bispecific fusion polypeptide comprises a fynomer sequence that binds to interleukin-17a (IL-17a) and forms a complex with an antibody that binds to interleukin-6 receptor (IL-6R) or a subsequence thereof having IL-6R binding ability, the fynomer sequence maintains the motifs at positions 12 to 17 and the motifs at positions 31 to 36 of the amino acid sequence of any one of SEQ ID NOs: 1 to 7 and has at least 90% identity with said amino acid sequence, and the bispecific fusion polypeptide binds to both IL-17a and IL-6R and inhibits the activity of both.
Citation Information
Patent Citations
Pharmaceutical composition comprising antibody-fynomer conjugate
JP2017057201A
Antibody-fynomer conjugates
WO2015141862A1
Novel use of melanocortin-1 receptor agonist
WO2023145959A1
